Page last updated: 2024-12-07

bexarotene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Bexarotene is a synthetic retinoid, a type of compound chemically similar to vitamin A. It is used as a medication for cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Bexarotene exerts its effects by binding to the retinoid X receptor (RXR), a nuclear receptor involved in gene regulation. This binding triggers a cascade of events that ultimately leads to the suppression of cell growth and the induction of apoptosis (programmed cell death) in cancer cells. Its importance lies in its ability to target and kill cancerous cells while sparing healthy cells. Bexarotene is studied due to its promising potential for treating various cancers, including multiple myeloma, leukemia, and breast cancer. Research also investigates its potential for other conditions like psoriasis and diabetic retinopathy. Bexarotene is typically administered orally and can cause various side effects, including high cholesterol levels, liver problems, and bone loss. It is important to note that this description is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new medications or treatments.'

Cross-References

ID SourceID
PubMed CID82146
CHEMBL ID1023
CHEBI ID50859
SCHEMBL ID9025
MeSH IDM0250478

Synonyms (133)

Synonym
BIDD:PXR0021
CHEMBL1023 ,
nsc-747528
bdbm50032675
HY-14171
unii-a61rxm4375
lg 69
lg 100069
nsc 741061
targret
a61rxm4375 ,
bexarotene [usan:inn:ban]
nsc 747528
gtpl2807
bexarotene (jan/usan/inn)
D03106
153559-49-0
targretin (tn)
benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-
4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
lg100069
lgd 1069
bexarotene [usan]
lg 1069
targrexin
p-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
hsdb 7453
targretyn
targretin
NCGC00181016-01
CHEBI:50859 ,
bexaroteno
bexarotenum
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
bexarotene ,
DB00307
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
lgd-1069
3-methyl-ttneb
lgd1069
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
HMS2089L14
lg-100069
FT-0657110
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid
A809441
nsc747528
benzoic acid,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-
NCGC00181016-03
NCGC00181016-02
4-[1-(3,5,5,8,8-pentamethyl-2-5,8-dihydronaphthyl)vinyl]benzoic acid
NCGC00255426-01
cas-153559-49-0
dtxcid9020619
tox21_302407
dtxsid1040619 ,
tox21_112666
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]benzoic acid
BCP9000396
sr 11247
ro 26-4455
BCP0726000106
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid
4K6I
CS-0626
AKOS015902814
S2098
bexarotene [inn]
bexarotene [mi]
bexarotene [mart.]
bexarotene [orange book]
bexarotene [who-dd]
bexarotene [hsdb]
bexarotene [jan]
bexarotene [ema epar]
bexarotene [vandf]
CCG-221823
DL-298
MLS006010146
smr001614557
SCHEMBL9025
NCGC00181016-04
tox21_112666_1
SS-4628
AB01275475-01
4-[1-(1,1,4,4,7-pentamethyltetralin-6-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl]benzoic acid
4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid
NAVMQTYZDKMPEU-UHFFFAOYSA-N
4,6-dichloro-2,3-dihydro-1h-indolehydrochloride
166175-31-1
AC-24569
B4798
AB01275475_02
mfcd00932428
bexarotene oral(targretin)
J-519847
SR-05000001480-2
sr-05000001480
HMS3655D19
bexaroten
SR-05000001480-1
bexarotene, >=98% (hplc)
J-009026
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl)benzoic acid
NCGC00181016-08
SW203810-3
FT-0702645
BCP04099
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-vinyl]benzoic acid
Q418192
AMY24869
BRD-K92441787-001-02-5
SB17341
NCGC00181016-20
HMS3884B07
HMS3747C21
nsc-783322
nsc783322
4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
BB164246
bexarotene- bio-x
EN300-19769221
bexarotene (mart.)
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl)benzoic acid
4-(1-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl)benzoic acid
l01xx25
3-methyl ttneb
4-(1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl)benzoic acid

Research Excerpts

Overview

Bexarotene is an FDA-approved drug for the treatment of cutaneous T-cell lymphoma. Its use provokes or disrupts other retinoid-X-receptor (RXR)-dependent nuclear receptor pathways and thereby incites side effects.

ExcerptReferenceRelevance
"Bexarotene is a specific retinoid X receptor agonist that has been used for the treatment of cutaneous T-cell lymphoma (CTCL). "( Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N, 2022
)
2.39
"Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. "( Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.
Brown, PH; Contreras, A; Dimond, E; Heckman-Stoddard, BM; Hernandez, M; Khan, SA; Lee, JJ; Liu, DD; Mays, C; Muzzio, M; Patel, AB; Perloff, M; Sepeda, V; Thomas, PS; Vornik, LA; Weber, D, 2023
)
2.62
"Bexarotene is an FDA-approved drug for the treatment of cutaneous T-cell lymphoma (CTCL); however, its use provokes or disrupts other retinoid-X-receptor (RXR)-dependent nuclear receptor pathways and thereby incites side effects including hypothyroidism and raised triglycerides. "( An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
di Martino, O; Ivan, DJ; Jurutka, PW; Khadka, I; Krall, TD; Le, A; Lee, IJ; Lee, MY; Liu, W; Mallick, S; Marshall, PA; Moen, GA; Noh, Y; Peoples, SJ; Perez, A; Petros, R; Reshi, S; Salama, E; Salama, J; Sausedo, MA; Savage, BM; Tromba, L; Wagner, CE; Welch, JS; Ziller, JW, 2022
)
2.36
"Bexarotene (BEX) is a specific RXR agonist and an antineoplastic agent indicated by the FDA for cutaneous T-cell lymphoma (CTLA)."( Design, synthesis and characterization of a novel multicomponent salt of bexarotene with metformin and application in ameliorating psoriasis with T2DM.
An, Q; Du, G; Hao, Y; Li, W; Lu, Y; Ren, L; Wang, J; Yang, D; Yang, H; Yang, Y; Yu, M; Zhang, S; Zhang, Y, 2023
)
1.86
"Bexarotene is a novel selective RXR ligand used in the treatment of T‑cell lymphoma."( Activation of RXR by bexarotene inhibits inflammatory conditions in human rheumatoid arthritis fibroblast‑like synoviocytes.
Han, X; Li, Y; Wang, J; Wei, Y; Xing, Q; Zhang, P; Zhao, L, 2019
)
1.55
"Bexarotene is a retinoid X receptor (RXR) agonist used for the treatment of T-cell lymphoma and other cancers which has displayed a favourable safety profile."( The protective effects of bexarotene against advanced glycation end-product (AGE)-induced degradation of articular extracellular matrix (ECM).
Han, Q; Huo, S; Zha, Z, 2020
)
1.58
"Bexarotene is a third-generation retinoid X receptor agonist that is promising in the treatment of both cancer and neurodegenerative diseases."( Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARγ/ NF-κB signaling pathway in C6 glioma cells.
Hacioglu, C; Kacar, S; Kanbak, G; Kar, F; Sahinturk, V, 2021
)
2.79
"Bexarotene is a third-generation retinoid that inhibits epithelial cell proliferation and is approved for treatment of advanced CTCL (stages IIB-IVB) in adult patients who have failed at least 1 prior systemic therapy."( Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.
Eshagh, K; Romero, LS; So, JK; Zhao, XF, 2017
)
1.57
"Bexarotene is a specific RXRs agonist which has been granted by FDA approval for the clinical treatment of cutaneous T cell lymphoma (CTCL)."( Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers.
Chen, Y; Cheng, F; Li, G; Shen, D; Wu, Y; Xia, L; Yu, X, 2018
)
1.54
"Bexarotene is an RXR pharmacological agonist that is shown to be neuroprotective through its effects in promoting amyloid beta (Aβ) uptake by the glial cells in the brain."( Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.
Abbasi, M; Chitranshi, N; Chung, R; Dheer, Y; Graham, SL; Gupta, V; Mirzaei, M; You, Y, 2018
)
2.64
"Bexarotene is an agonist of retinoid X receptor and plays a protective role in central nervous system diseases."( Bexarotene attenuates early brain injury via inhibiting micoglia activation through PPARγ after experimental subarachnoid hemorrhage.
Liu, D; Qu, X; Tian, JY; Tian, T; Tu, L; Wang, Q; Yang, XL; Zhang, Q, 2018
)
2.64
"Bexarotene is a pleiotropic molecule that has been proposed as an amyloid-β (Aβ)-lowering drug for the treatment of Alzheimer's disease (AD). "( Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its α-Helical Conformation, and Inhibits γ-Secretase Nonselectively in Liposomes.
Basset, G; Heinel, H; Huster, D; Hutchison, JM; Kamp, F; LaPointe, LM; Sanders, CR; Scheidt, HA; Steiner, H; Winkler, E, 2018
)
3.37
"Bexarotene is an anticancer drug that has been under consideration for its ability to suppress Aβ-peptide aggregation."( Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach.
Batool, A; Bibi, N; Kamal, MA; Rizvi, SMD, 2019
)
1.5
"Bexarotene is a retinoid that specifically binds retinoid X receptors and has numerous effects on cellular growth and differentiation. "( Topical and oral bexarotene.
Schadt, CR,
)
1.91
"Bexarotene (Targretin®) is a synthetic retinoid that selectively activates the retinoid X receptor subfamily of retinoid receptors and exhibits potent anti-tumor activity. "( Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation.
Chen, L; Guo, H; Hao, L; Lou, H; Wang, Y; Zhang, D; Zhang, J, 2014
)
3.29
"Bexarotene (Bex) is a synthetic retinoid that exhibits anti-tumor activities. "( Preparation, in vitro and in vivo evaluation of bexarotene nanocrystals with surface modification by folate-chitosan conjugates.
Chen, L; Li, L; Liu, Y; Wang, J; Yan, X; Zhang, W, 2016
)
2.13
"Bexarotene is a retinoid X receptor (RXR) ligand with anti-angiogenic activity."( Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.
Escudero, P; Ferrando, C; Furio, E; Gonzalez-Navarro, H; Juez, M; Navarro, A; Piqueras, L; Sanz, MJ, 2015
)
1.45
"Bexarotene gel is a topical retinoid used in the treatment of CTCL."( Woringer-Kolopp (Pagetoid Reticulosis) disease successful response to bexarotene gel.
Groysman, V; Ledet, J; Sami, N,
)
1.09
"Bexarotene is a drug already used clinically to treat cancer, and it has the ability to enhance the commitment of embryonic stem cells into skeletal muscle lineage."( Retinoid X Receptor-selective Signaling in the Regulation of Akt/Protein Kinase B Isoform-specific Expression.
Aabed, K; AlSudais, H; Chen, J; Dixon, K; Li, Q; Nicola, W, 2016
)
1.16
"Bexarotene is a synthetic retinoid effective in early and advanced stages of mycosis fungoides (MF)/Sezary Syndrome (SS) both in monotherapy and combination schemes. "( Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Alterini, R; Brandozzi, G; Canafoglia, L; Federici, I; Filosa, G; Giantomassi, F; Goteri, G; Leoni, P; Micucci, G; Mozzicafreddo, G; Pimpinelli, N; Ricotti, G; Rupoli, S; Scortechini, AR; Simonacci, M; Zizzi, A,
)
1.82
"Bexarotene is a retinoid X receptor agonist, which is currently used for the treatment of cutaneous T-cell lymphoma (CTCL). "( Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy.
Basani, S; Garg, A,
)
1.8
"Bexarotene is a synthetic selective X receptor rexinoide approved for the systemic treatment of cutaneous T-cell lymphoma. "( [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S, 2016
)
2.13
"Bexarotene is a nuclear retinoid X receptor agonist."( [Endocrine complications of modern cancer therapy].
Čáp, J,
)
0.85
"Bexarotene is an oral retinoid approved for treating cutaneous T-cell lymphoma (CTCL) in patients resistant to first-line systemic treatment. "( Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O, 2017
)
2.15
"Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer's disease is being investigated. "( Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain.
Gray, GM; Ma, N; van der Vaart, A; Wagner, CE, 2017
)
1.9
"Bexarotene is a retinoic X receptor agonist that has been shown in vitro to inhibit growth and induce differentiation of myeloid leukemic cell lines. "( A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Andreadis, C; Bagg, A; Carroll, M; Goldstein, SC; Goradia, A; Kemner, A; Loren, AW; Luger, SM; Mato, AR; Perl, AE; Porter, DL; Potuzak, M; Schuster, SJ; Stadtmauer, EA; Swider, C; Thompson, JE; Tsai, DE; Vogl, DT, 2008
)
2.12
"Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL)."( Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott, RA; Bashir, SJ; Hung, T; Morris, SL; Russell-Jones, R; Scarisbrick, JJ; Whittaker, SJ, 2009
)
3.24
"Bexarotene (Targretin) is a clinically used antitumoral agent which exerts its action through binding to and activation of the retinoid-X-receptor (RXR). "( Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.
Fiévet, C; Gross, B; Gustafsson, JA; Lalloyer, F; Lestavel, S; Mandrup, S; Pedersen, TA; Staels, B; Tailleux, A; Vallez, E; Yous, S, 2009
)
2.21
"Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer."( Bexarotene: a promising anticancer agent.
Qu, L; Tang, X, 2010
)
2.52
"Bexarotene is an RXR-selective vitamin A analog that has been shown to prevent ER-negative mammary tumorigenesis in animal models. "( The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.
Bissonnette, RP; Brown, PH; Kim, HT; Lamph, WW; Li, Y; Shen, Q; Yan, B, 2011
)
2.18
"Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lym-phoma (CTCL). "( Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Hahtola, S; Ranki, A; Väkevä, L, 2012
)
2.13
"Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors. "( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
2.08
"Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma."( Bexarotene is a new treatment option for lymphomatoid papulosis.
Duvic, M; Krathen, RA; Ward, S, 2003
)
2.48
"Bexarotene is a retinoid X receptor-selective retinoid that has preclinical antitumor activity in breast cancer. "( Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Baidas, S; Cohen, R; Demetri, GD; DeMichele, A; Dickler, M; Esteva, FJ; Glaspy, J; Hayes, DF; Hortobagyi, GN; Hutchins, L; Laufman, L; Osborne, CK; Tripathy, D; Winer, E; Yocum, RC, 2003
)
2.04
"Bexarotene is a synthetic retinoid X receptor (RXR)-selective retinoid recently approved for treatment of cutaneous T-cell lymphoma. "( Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
Sherman, SI, 2003
)
1.98
"Bexarotene is a synthetic retinoid analog that selectively activates retinoid X receptors."( Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin, AG, 2003
)
2.48
"Bexarotene is a novel retinoid X receptor (RXR)-selective ligand."( A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion.
Franssen, ME; Smit, JV; Van De Kerkhof, PC; Van Erp, PE, 2003
)
1.28
"Bexarotene is a newly registered drug."( [Standard and experimental therapy of cutaneous T-cell lymphoma].
Beyeler, M; Dummer, R, 2003
)
1.04
"Bexarotene is an RXR-selective retinoid that can induce apoptosis of mycosis fungoides (MF) and Sézary syndrome (SS) cells."( The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
Andreeff, M; Duvic, M; Konopleva, M; Ni, X; Zhang, C, 2004
)
1.04
"Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. "( Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis, SA; Davis, MD; el-Azhary, RA; Gibson, LE; Kist, JM; Knudsen, JM; McEvoy, MT; Pittelkow, MR, 2005
)
3.21
"Bexarotene (Targretin), is a synthetic high-affinity RXR receptor agonist with limited affinity for RAR receptors. "( Prevention of lung cancer progression by bexarotene in mouse models.
Jia, D; Lubet, RA; Wang, D; Wang, Y; Yao, R; You, M; Zhang, Z, 2006
)
2.04
"Bexarotene is a new retinoid x receptor-specific retinoid that has been approved for systemic second-line therapy for cutaneous T-cell lymphomas in the USA and Europe."( Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W, 2003
)
2.48
"Bexarotene is an X receptor-specific retinoid with anti-tumor activity."( [Treatment of cutaneous T-cell lymphomas with bexarotene].
Acebo, E; Díaz-Pérez, JL; Eguino, P; Izu, R; Lasa, O, 2005
)
1.31
"Bexarotene is an effective therapeutic option in this heterogeneous group of diseases."( [Treatment of cutaneous T-cell lymphomas with bexarotene].
Acebo, E; Díaz-Pérez, JL; Eguino, P; Izu, R; Lasa, O, 2005
)
1.31
"Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies. "( Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S, 2006
)
2.04
"Bexarotene is a rexinoid (selective retinoid X receptor agonist) that affects proliferation, differentiation, and apoptosis in preclinical studies. "( A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Black, CC; Dmitrovsky, E; Dragnev, KH; Hermann, T; Lewis, LD; Memoli, V; Negro-Vilar, A; Nugent, WC; Petty, WJ; Rigas, JR; Shah, SJ, 2007
)
2.05
"Bexarotene is a novel synthetic compound that selectively binds and activates retinoic X receptors, a subclass of retinoid receptors not targeted by ATRA."( Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
DiNardo, CD; Forfia, P; Ky, B; Loren, A; Luger, S; Mato, A; Tsai, DE; Vogl, DT, 2008
)
1.28
"Bexarotene is a synthetic retinoid used for treatment of neoplastic or dermatologic disorders. "( Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Gibel, A; Goodman, AB; Kovalyonok, E; Lerner, V; Miodownik, C; Ritsner, MS; Shleifer, T,
)
3.02
"Bexarotene was found to be a safe medication as measured by all laboratory parameters with the exception of increased total cholesterol serum level."( Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Gibel, A; Goodman, AB; Kovalyonok, E; Lerner, V; Miodownik, C; Ritsner, MS; Shleifer, T,
)
2.3
"Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FME The case of a 73-year-old male with FMF that responded to bexarotene gel is presented."( Folliculotropic mycosis fungoides responding to bexarotene gel.
Gerami, P; Scupham, RK; Swick, BL; Walling, HW, 2008
)
1.32
"Bexarotene is a selective retinoid X receptor (RXR) agonist. "( Bexarotene.
Lowe, MN; Plosker, GL,
)
3.02

Effects

Bexarotene has been investigated in the treatment of breast cancer and non-small cell carcinoma of the lung. It has been found to improve neurological function in mice in an ApoE-dependent manner, but the detailed mechanism is not fully clear.

ExcerptReferenceRelevance
"Bexarotene has been found to improve neurological function in mice in an ApoE-dependent manner, but the detailed mechanism is not fully clear."( Inhibition of MAPT enhances the effect of bexarotene and attenuates the damage after traumatic brain injury using in vivo and in vitro experiments.
Dong, H; Wang, H; Wang, L, 2020
)
1.54
"Bexarotene has been demonstrated to protect neurons in CNS diseases."( Bexarotene protects against neurotoxicity partially through a PPARγ-dependent mechanism in mice following traumatic brain injury.
Cheng, C; Guo, Z; He, J; Huang, Z; Jiang, L; Li, H; Liu, H; Liu, L; Qi, L; Sun, X; Wu, J; Wu, Y; Zhang, H; Zhang, Z; Zhong, J, 2018
)
2.64
"Bexarotene has shown inhibition of lung and mammary gland tumorigenesis in preclinical models and in clinical trials. "( Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice.
Chen, X; Lee, SB; Lubet, RA; Miller, MS; Mirza, SP; Pan, J; Stevenson, ME; Wang, Y; Xiong, D; You, M; Zhang, Q; Zhou, Y, 2019
)
2.36
"Bexarotene has been reported to reduce brain amyloid-β (Aβ) levels and to improve cognitive function in transgenic mouse models of Alzheimer's disease (AD). "( Lack of support for bexarotene as a treatment for Alzheimer's disease.
Barbour, B; Guo, JP; Hanna, D; Hobson, P; Jeggo, R; Kim, EM; Lyons, T; McGeer, EG; McGeer, PL; Meara, JR; O'Hare, E; Page, D; Palmer, P; Spanswick, D; Walczak, JS, 2016
)
2.2
"Bexarotene has been proved to have a specifically favorable therapeutic profile in clinical dermatology or oncology with mild or absent retinoids side effects, especially in combination with other therapies."( Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.
Cao, X; Guo, Y; Luan, Y; Qi, L; Zhang, P, 2016
)
1.39
"Bexarotene has been proved to have neuroprotective effects in many animal models of neurological diseases. "( Bexarotene protects against traumatic brain injury in mice partially through apolipoprotein E.
Cao, F; Cheng, C; He, J; Huang, Z; Jiang, L; Liu, H; Sun, X; Teng, Z; Wu, J; Wu, Y; Zhang, H; Zhong, J, 2017
)
3.34
"Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL."( CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A, 2008
)
1.31
"Bexarotene has the same effect as its natural counterpart: 9-cis-retinoic acid."( Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto, C; Gurioli, C; Neri, I, 2010
)
1.34
"Bexarotene has been demonstrated to act on malignant T-cells by inducing their apoptosis, but nothing is known about its role on keratinocytes and Langerhans cells."( About the cutaneous targets of bexarotene in CTCL patients.
Ballanger, F; Brocard, A; Dréno, B; Khammari, A; Knol, AC; Nguyen, JM; Quéreux, G, 2010
)
1.37
"Bexarotene, which has been reported to alter keratin synthesis, caused vesiculobullous reactions with similar frequency in clinical trials."( A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote.
Bosenberg, MW; Carlson, KR; Girardi, M; Kreizenbeck, GM; Muthusamy, V; Trufant, JW, 2010
)
1.31
"Bexarotene has recently been approved in the United States and Europe as a single orally administered retinoid for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. "( Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Lebwohl, M; Stern, DK, 2002
)
2.02
"Bexarotene has also been investigated in the treatment of breast cancer and non-small cell carcinoma of the lung with promising early results."( Bexarotene: a clinical review.
Farol, LT; Hymes, KB, 2004
)
2.49
"Bexarotene has shown efficacy in a phase I/II trial of non-small-cell lung cancers."( Prevention of lung cancer progression by bexarotene in mouse models.
Jia, D; Lubet, RA; Wang, D; Wang, Y; Yao, R; You, M; Zhang, Z, 2006
)
1.32
"Bexarotene has demonstrated chemopreventive and therapeutic efficacy towards mouse lung tumors. "( Modulation by bexarotene of mRNA expression of genes in mouse lung tumors.
Alyaqoub, FS; Liu, Y; Lubet, RA; Pereira, MA; Steele, VE; Tao, L, 2008
)
2.15
"Bexarotene has demonstrated activity in the treatment of CTCL. "( Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
Wong, SF, 2001
)
2.27

Actions

Bexarotene could enhance this effect and reverse the Aβ25-35-induced decrease in the firing rate of the action potential (AP) The drug appears to lower the C max and AUC0-24 of gefitinib through cytochrome P450 CYP3A4.

ExcerptReferenceRelevance
"Bexarotene appears to lower the C max and AUC0-24 of gefitinib through cytochrome P450 CYP3A4."( Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L, 2013
)
1.38
"Bexarotene could enhance this effect and reverse the Aβ25-35-induced decrease in the firing rate of the action potential (AP)."( Protective effects of bexarotene against amyloid-β25-35-induced dysfunction in hippocampal neurons through the insulin signaling pathway.
Chen, T; Dai, W; Yang, J; Yang, Z, 2014
)
1.44
"Bexarotene produce as predictable side effects severe mixed hyperlipidemia with marked decrease in HDL-cholesterol levels and central hypothyroidism, being the both reversible and dose-dependent. "( [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S, 2016
)
2.13
"Bexarotene tended to increase ceramide abundance, an effect, however, not reaching statistical significance."( Triggering of Suicidal Erythrocyte Death by Bexarotene.
Al Mamun Bhuyan, A; Bissinger, R; Cao, H; Lang, F, 2016
)
1.42

Treatment

Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase. Treatment not only rescued the RXR expression loss caused by Aβ treatment (p < 0.05) but also protected the cells against Aβ-induced ER stress.

ExcerptReferenceRelevance
"Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase (MMP)‑1, MMP‑3 and MMP‑13."( Activation of RXR by bexarotene inhibits inflammatory conditions in human rheumatoid arthritis fibroblast‑like synoviocytes.
Han, X; Li, Y; Wang, J; Wei, Y; Xing, Q; Zhang, P; Zhao, L, 2019
)
1.55
"Bexarotene is used for treatment-resistant early stage MF and advanced stages of the disease."( Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene.
Gulekon, A; Tamer, F, 2021
)
1.57
"All bexarotene-treated participants had at least one adverse event, which included central hypothyroidism (n=26 vs none on placebo), hypertriglyceridaemia (n=24 vs none on placebo), rash (n=13 vs one on placebo), and neutropenia (n=10 vs none on placebo)."( Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Altmann, DR; Brown, JWL; Chandran, S; Chard, DT; Coles, AJ; Connick, P; Cunniffe, NG; Ffrench-Constant, C; Flynn, PD; Franklin, RJM; Gandini Wheeler-Kingshott, CAM; Georgieva, Z; Jones, JL; Kanber, B; MacManus, D; Michell, AW; Moran, C; Needham, E; Overell, J; Pearson, OR; Prados, F; Rog, D; Samson, RS; Stutters, J, 2021
)
1.41
"Bexarotene treatments exert neuroprotective effects on mice following traumatic brain injury (TBI). "( The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice.
Cheng, C; Darwazeh, R; He, J; Huang, Z; Jiang, L; Liu, H; Sun, X; Wu, J; Wu, Y; Zhang, H; Zhong, J, 2017
)
2.12
"Bexarotene treatment enhanced cognition in APP/PS1 mice similar to previous findings. "( Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
Casali, BT; Landreth, GE; Reed-Geaghan, EG, 2018
)
1.92
"Bexarotene treatment not only rescued the RXR expression loss caused by Aβ treatment (p < 0.05) but also protected the cells against Aβ-induced ER stress (p < 0.05) and pro-apoptotic BAD protein activation (p < 0.05)."( Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.
Abbasi, M; Chitranshi, N; Chung, R; Dheer, Y; Graham, SL; Gupta, V; Mirzaei, M; You, Y, 2018
)
2.64
"Bexarotene treatment significantly reduced brain edema and improved the short-/long-term neurological deficit after SAH."( Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats.
Enkhjargal, B; Huang, L; Liu, F; Tang, J; Travis, ZD; Umut, O; Xu, W; Zhang, G; Zhang, JH; Zuo, Y, 2019
)
1.51
"Bexarotene treatment could attenuate arteriosclerosis progression in STZ induced diabetic apoE(-/-) mice, the underlying mechanism might be related to suppressing oxidative stress and decreasing blood glucose level and improving lipids metabolism."( [Effects and related mechanism of retinoid X receptor agonist bexarotene on atherosclerosis progression in diabetic apoE(-/-) mice].
Chai, D; Lin, J; Ning, R; Xu, C; Zhu, J, 2014
)
2.09
"Upon bexarotene treatment, levels of brain apoE and ATP-binding cassette sub-family A member 1 (ABCA1) were significantly increased in both mice."( Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.
Bu, G; Kanekiyo, T; Liu, CC; Rogers, J; Shinohara, M; Tachibana, M; Yamazaki, Y, 2016
)
1.17
"Bexarotene treatment reduced nestin expression, while significantly increasing glial fibrillary acidic protein (GFAP) expression."( Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.
Cho, H; Choi, G; Heo, JC; Hwang, D; Jung, D; Jung, M; Jung, TH; Kim, HY; Lee, HK; Lee, JO; Lee, S; Park, JH; Seol, HJ, 2016
)
1.56
"Bexarotene treatment induced I-131 uptake in metastases of 8 out of 11 patients (one patient died for reasons not related to the study). "( Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP, 2006
)
3.22
"Bexarotene treatment at a dose of 250 mg/kg diet was associated with reductions in tumor multiplicity of 84% (P < 0.0001) and 86% (P < 0.0001) in intact and ovariectomized animals, respectively."( Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
Brose, HL; Gould, MN; Haag, JD; Hitt, AA; Hu, R; Kim, K; Lindstrom, MJ; Lubet, RA; Mau, B; Monson, DM; Steele, VE; Waller, JL; Watson, PA; Woditschka, S; Zheng, Y, 2006
)
1.06
"Bexarotene treatment was well tolerated."( A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Black, CC; Dmitrovsky, E; Dragnev, KH; Hermann, T; Lewis, LD; Memoli, V; Negro-Vilar, A; Nugent, WC; Petty, WJ; Rigas, JR; Shah, SJ, 2007
)
1.33
"Bexarotene pretreatment induced radioiodine uptake in metastases in all eight patients, although uptake was only discernable at single photon emission computed tomography (SPECT) and had incomplete matching with the metastases visualized by CT scanning. "( Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP, 2008
)
2.05
"Bexarotene-treated patients with grade 3/4 hypertriglyceridemia who received the most benefit included those who were male, were smokers, experienced 6-month prior weight loss >or= 5%, and had stage IV disease."( Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein, GR; Dziewanowska, ZE; Gatzemeier, U; Jotte, RM; Khuri, FR; Le Treut, J; Miller, WH; Negro-Vilar, A; Sun, SL; von Pawel, J; Zhang, JK, 2008
)
1.31
"Bexarotene treatment at 1 and 10 microM for 96 h increased the number of cells with sub-G1 populations and annexin V binding in a dose-dependent manner compared with vehicle controls (DMSO) in all three cell lines, respectively. "( Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Duvic, M; Hazarika, P; Ni, X; Weidner, DA; Zhang, C, 2002
)
2.06
"Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin. "( Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Duvic, M; Hazarika, P; Ni, X; Weidner, DA; Zhang, C, 2002
)
2.06
"Treatment with bexarotene increased estradiol levels as well as estrogen-synthesizing enzymes and CYP19 expression in hippocampal slice cultures."( Retinoid X receptor-mediated neuroprotection via CYP19 upregulation and subsequent increases in estradiol synthesis.
Ishihara, Y; Oguro, A; Sakurai, H; Tsuji, M; Vogel, CFA; Yamazaki, T, 2019
)
0.85
"Co-treatment with bexarotene plus rosuvastatin reduced aneurysm formation, inflammation and neovascularization compared with each single treatment. "( Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.
Escudero, P; Ferrando, C; Furio, E; Gonzalez-Navarro, H; Juez, M; Navarro, A; Piqueras, L; Sanz, MJ, 2015
)
1.06
"The treatment with bexarotene does not seem to affect the regulatory T-cell compartment."( Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Ballanger, F; Brocard, A; Dréno, B; Khammari, A; Knol, AC; Nguyen, JM; Quéreux, G, 2010
)
0.9
"Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05)."( Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.
Lubet, RA; Wang, Y; Wen, W; Yi, Y; You, M; Zhang, Z, 2009
)
0.98

Toxicity

Central hypothyroidism is a well-recognized side effect of bexarotene. Participants who received bexrotene had a higher mean number of adverse events than did participants who received placebo.

ExcerptReferenceRelevance
" The most frequent drug-related adverse events included hypertriglyceridemia (associated rarely with pancreatitis), hypercholesterolemia, hypothyroidism, and headache."( Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Breneman, D; Crowley, C; Duvic, M; Heald, P; Hymes, K; Martin, AG; Myskowski, P; Yocum, RC, 2001
)
1.75
" Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose."( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
0.94
" Central hypothyroidism is a well-recognized side effect of bexarotene."( Thyroid dysfunction as an unintended side effect of anticancer drugs.
Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F, 2013
)
0.63
" Common drug-related adverse events in the FAS population included hypothyroidism (93."( Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
Hamada, T; Iwatsuki, K; Kawai, K; Kiyohara, E; Matsushita, S; Nagatani, T; Ohtsuka, M; Saida, T; Setoyama, M; Sugaya, M; Tani, M; Tokura, Y; Tsuboi, R; Yonekura, K, 2019
)
0.8
" To enhance the BXR glioblastoma selectivity and cytotoxicity, we chemically modified it at the carboxyl group with either nitroethanolamine (NEA) bearing a NO-donating group (a well-known bioactivity enhancer; BXR-NEA) or with a dopamine (DA) moiety (to represent the highly toxic for various tumor cells N-acyldopamine family; BXR-DA)."( Novel bexarotene derivatives: Synthesis and cytotoxicity evaluation for glioma cells in 2D and 3D in vitro models.
Akasov, R; Akimov, MG; Bezuglov, VV; Burov, S; Dudina, PV; Gamisonia, AM; Gretskaya, NM; Markvicheva, E; Serkov, IV; Sherstyanykh, G; Zakharov, SS, 2020
)
1.04
" Participants who received bexarotene had a higher mean number of adverse events (6·12 [SD 3·09]; 159 events in total) than did participants who received placebo (1·63 [SD 1·50]; 39 events in total)."( Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Altmann, DR; Brown, JWL; Chandran, S; Chard, DT; Coles, AJ; Connick, P; Cunniffe, NG; Ffrench-Constant, C; Flynn, PD; Franklin, RJM; Gandini Wheeler-Kingshott, CAM; Georgieva, Z; Jones, JL; Kanber, B; MacManus, D; Michell, AW; Moran, C; Needham, E; Overell, J; Pearson, OR; Prados, F; Rog, D; Samson, RS; Stutters, J, 2021
)
1.23

Pharmacokinetics

Bexarotene was rapidly eliminated with a half-life of 2. The primary objective of this study was to determine whether repeated doses of bexarotenes affect pharmacokinetic parameters of paclitaxel or carboplatin in lung cancer patients.

ExcerptReferenceRelevance
" The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced non-small cell lung cancer."( A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Chu, Q; Jacobs, CD; Lopez-Anaya, A; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA, 2012
)
0.88
" Blood sampling to characterize the pharmacokinetic profiles of the chemotherapeutic agents with or without bexarotene was performed during cycle 1 (without concomitant bexarotene) and during cycle 2 (with concomitant bexarotene)."( A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Chu, Q; Jacobs, CD; Lopez-Anaya, A; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA, 2012
)
0.87
" This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination."( A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Wakelee, HA; Zatloukal, P, 2012
)
0.66
" This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate)."( The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P, 2012
)
0.96
" We studied the combination of bexarotene and gefitinib in the third-line treatment of advanced non-small-cell lung cancer to examine pharmacokinetic interactions and establish the maximum tolerated dose."( Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L, 2013
)
0.95
" The in vivo test was carried out in rats and pharmacokinetic parameters of the bexarotene solution and bexarotene nanocrystals were compared after gavage and intravenous administration."( Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation.
Chen, L; Guo, H; Hao, L; Lou, H; Wang, Y; Zhang, D; Zhang, J, 2014
)
2.07
" A preclinical pharmacokinetic study was pursued in control, chronic kidney disease (CKD), and acute kidney injury (AKI) rats."( In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human.
Alsmadi, MM; Alzughoul, SB, 2023
)
1.19

Compound-Compound Interactions

This study aimed to assess the long-term tolerability of pralatrexate alone or in combination with oral bexarotene for relapsed or refractory mycosis fungoides (MF) The MTD of docetaxel was 30 mg/m(2) in combination.

ExcerptReferenceRelevance
"Forty-three patients who had stage IIIB NSCLC with pleural effusion or stage IV NSCLC and had received no prior therapy received bexarotene in combination with cisplatin (100 mg/m2) and vinorelbine (alternating doses of 30 mg/m2 and 15 mg/m2)."( Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
Figlin, RA; Fox, N; Gralla, RJ; Hong, WK; Huyghe, MR; Kean, Y; Khuri, FR; Munden, R; Reich, SD; Rigas, JR; Shin, DM, 2001
)
0.78
" We describe a 47-year old female with a 4-year history of mycosis fungoides (MF) who developed debilitating side effects from acitretin and PUVA, and subsequently responded to bexarotene 75 mg orally once daily combined with PUVA."( Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Lebwohl, M; Stern, DK, 2002
)
0.77
" In advanced stages of CTCL, liposomal-encapsulated doxorubicin or extracorporeal photopheresis may be combined with bexarotene or IFNalpha."( Optimal combination with PUVA: rationale and clinical trial update.
Stadler, R, 2007
)
0.55
" conclusion: The MTD of docetaxel was 30 mg/m(2) in combination with daily bexarotene at 400mg/m(2)."( A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
Collins, B; Hwang, J; Malik, SM; Marshall, J; Pishvaian, M; Ramzi, P, 2011
)
0.93
"This study aimed to assess the long-term tolerability of pralatrexate alone or in combination with oral bexarotene for relapsed or refractory mycosis fungoides (MF)."( Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Duvic, M; Gangar, P; Talpur, R; Thompson, A, 2014
)
0.88
" During a second phase I/II dose-ranging combination trial, participants were treated with pralatrexate at 15 mg/m(2)/wk for 3 of 4 weeks combined with 150 to 300 mg/m(2) of daily oral bexarotene."( Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Duvic, M; Gangar, P; Talpur, R; Thompson, A, 2014
)
0.86
"Pralatrexate alone or in combination with low-dose oral bexarotene is well tolerated and capable of providing long-term responses in patients of advanced age with advanced-stage MF."( Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Duvic, M; Gangar, P; Talpur, R; Thompson, A, 2014
)
0.91

Bioavailability

Bexarotene is highly toxic and poor-water soluble. It has low bioavailability in the conventional pharmaceutical forms.

ExcerptReferenceRelevance
" However, the poor solubility and bioavailability limit its application."( Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation.
Chen, L; Guo, H; Hao, L; Lou, H; Wang, Y; Zhang, D; Zhang, J, 2014
)
1.85
" Bexarotene is highly toxic and poor-water soluble, having low bioavailability in the conventional pharmaceutical forms."( Development of New Bexarotene-loaded Mesoporous Silica Systems for Topical Pharmaceutical Formulations.
Draganescu, D; Dumitras, M; Ignat, M; Ochiuz, L; Sacarescu, L; Stoleriu, I; Vasile, A; Zaltariov, MF, 2018
)
1.72
" In this study, we have incorporated in vitro lipolysis with microsomal stability to quantitatively predict the oral bioavailability of a lipophilic antineoplastic drug bexarotene (BEX) administered in LBDDS."( Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach.
Choi, HG; Feng, W; Gershkovich, P; Kim, TH; Lee, JB; Shin, BS; Shin, S; Yoo, SD; Zgair, A, 2019
)
0.93
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. The method was applied to investigate the plasma pharmacokinetics and brain distribution of bexarotenes in mice.

ExcerptRelevanceReference
" However, no significant dose-response effect was found."( A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion.
Franssen, ME; Smit, JV; Van De Kerkhof, PC; Van Erp, PE, 2003
)
0.56
" Furthermore, there appears to be no standardization of dosing among physicians who treat CTCL."( Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
Crawford, G; Junkins-Hopkins, JM; McGinnis, KS; Rook, AH; Shapiro, M; Vittorio, CC, 2004
)
0.68
" No significant dose-response effect was established for these parameters."( A phase II multicenter clinical trial of systemic bexarotene in psoriasis.
de Jong, EM; De Weert, J; Franssen, ME; Lambert, J; Roseeuw, DI; Smit, JV; Stevens, VJ; van De Kerkhof, PC; Yocum, RC, 2004
)
0.58
" Apart from a weak significant dose-response effect for Ki-67, no other significant dose-response effects were seen."( Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
Boezeman, JB; de Jong, EM; Otero, ME; Smit, JV; van de Kerkhof, PC; van Hooijdonk, CA, 2004
)
0.58
" Three experiments were performed: (i) a dose-response study with vinyl carbamate-induced tumors; (ii) a limited treatment study also with vinyl carbamate and (iii) prevention of NNK-induced tumors."( Prevention of mouse lung tumors by targretin.
Alyaqoub, FS; Gunning, WT; Kramer, PM; Liu, Y; Lubet, RA; Nines, R; Pereira, MA; Steele, VE, 2006
)
0.33
" Although combinations of oral bexarotene and psoralen plus UVA (PUVA) have been tried in patients with all stages of mycosis fungoides (MF), the dosage of bexarotene used in these combination regimens has been variable."( Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Antoniou, C; Katsambas, A; Nikolaou, V; Papadavid, E; Siakantaris, M; Stavrianeas, N; Stratigos, A; Vassilakopoulos, TP, 2008
)
0.92
" Literature on the efficacy, dosing and side-effects of bexarotene is sparse."( Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Hahtola, S; Ranki, A; Väkevä, L, 2012
)
0.94
" statement outlining a bexarotene dosing schedule and monitoring protocol to enable bexarotene prescribers to deliver bexarotene safely for optimal effect."( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
0.95
" The statement outlines a bexarotene dosing schedule and monitoring protocol."( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
0.94
"In efforts to clarify these behavioral findings, mutant APP/PS1 mice were acutely dosed with bexarotene."( Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
Allard, JS; LaClair, KD; Lee, DL; Manaye, KF; Savonenko, AV; Troncoso, JC; Wong, PC, 2013
)
0.96
" Dose-response measurements were used to generate multiparameter drug sensitivity scores using R-statistical language."( Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
Af Hällström, TM; Aittokallio, T; Bychkov, D; Eldfors, S; Heckman, C; Horvath, P; Kallioniemi, O; Mirtti, T; Mpindi, JP; Östling, P; Paavolainen, L; Peehl, DM; Rahkama, V; Rannikko, A; Saeed, K; Wennerberg, K; Yadav, B, 2017
)
0.46
" After CCI, mice were daily dosed with bexarotene or vehicle solution intraperitoneally."( Bexarotene protects against traumatic brain injury in mice partially through apolipoprotein E.
Cao, F; Cheng, C; He, J; Huang, Z; Jiang, L; Liu, H; Sun, X; Teng, Z; Wu, J; Wu, Y; Zhang, H; Zhong, J, 2017
)
2.17
" Dose-response curves demonstrated that plasma concentrations observed in clinical trials are sufficient for LXR activation and thus could account for LXR-mediated side-effects such as hypercholesterolemia and hyperlipidemia."( DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
Achenbach, J; Heitel, P; Merk, D; Moser, D; Proschak, E, 2017
)
0.71
" TRH stimulation testing was performed following CH diagnosis, with LT4 replacement dosage adjusted to maintain F-T4 at the pre-treatment level."( Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022
)
2.16
" The method was applied to investigate the plasma pharmacokinetics and brain distribution of bexarotene in mice after being intragastrically administered with bexarotene at the dosage of 100 mg/kg."( A highly sensitive and rapid LC-MS/MS method for quantification of bexarotene in mouse plasma and brain tissue: Application to mice pharmacokinetic study.
Chen, G; Chu, L; Di, X; Fu, H; Jiao, H; Lin, L; Liu, Y; Wang, X; Zou, L, 2022
)
1.18
"Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities."( Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.
Brown, PH; Contreras, A; Dimond, E; Heckman-Stoddard, BM; Hernandez, M; Khan, SA; Lee, JJ; Liu, DD; Mays, C; Muzzio, M; Patel, AB; Perloff, M; Sepeda, V; Thomas, PS; Vornik, LA; Weber, D, 2023
)
2.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (84)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency45.74610.125919.1169125.8920AID2708
LuciferasePhotinus pyralis (common eastern firefly)Potency32.19680.007215.758889.3584AID624030
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency32.05053.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency25.78320.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency40.88680.173734.304761.8120AID1346924
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency22.38720.031637.5844354.8130AID504865
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency40.88680.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency3.75860.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency53.39700.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency27.78060.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743053; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency51.04060.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency43.68820.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.74940.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency47.51380.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.48710.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency24.93820.001310.157742.8575AID1259252; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency18.17760.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency6.11560.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency13.74690.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.11520.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency42.98680.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency19.33120.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.01440.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency43.64860.01238.964839.8107AID1645842
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.84800.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency19.12630.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency29.29000.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency51.04060.013326.981070.7614AID1346978
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency44.66840.016525.307841.3999AID602332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.13060.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency52.20380.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency56.01570.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency25.74370.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency46.662819.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency36.97340.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency44.66840.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency91.51830.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency51.04060.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency48.11670.540617.639296.1227AID2528; AID2585
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency11.22020.354828.065989.1251AID504847
caspase-3Cricetulus griseus (Chinese hamster)Potency51.04060.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.96730.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency31.94760.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency18.58100.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.78280.00798.23321,122.0200AID2551
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency22.14960.005612.367736.1254AID624032; AID624044
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency6.30960.251215.843239.8107AID504327
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency9.43980.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency32.97020.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency43.64860.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency21.63670.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency9.43980.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency3.16230.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency43.64860.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency30.63790.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency30.63790.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency43.64860.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Cytochrome P450 26A1Homo sapiens (human)IC50 (µMol)13.50000.00513.41257.8000AID1290556
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Cytochrome P450 1A2Homo sapiens (human)Ki0.37900.00561.15349.0000AID1615905
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)5.90000.00011.753610.0000AID1290555
Retinoic acid receptor alphaHomo sapiens (human)Ki2.81650.00100.94856.5000AID198055; AID200141
Retinoic acid receptor betaHomo sapiens (human)Ki2.70150.00071.56739.9010AID198224; AID198545
Retinoic acid receptor gamma Homo sapiens (human)Ki1.66800.00001.997510.0000AID198741; AID199056
Retinoic acid receptor RXR-alphaHomo sapiens (human)IC50 (µMol)0.63200.00600.44502.4000AID1710499
Retinoic acid receptor RXR-alphaHomo sapiens (human)Ki0.16470.00040.56927.6320AID1615902; AID1615905; AID1710499; AID1710500; AID199213; AID199639; AID438596
Retinoic acid receptor RXR-betaHomo sapiens (human)Ki0.01340.00050.15920.8810AID199232; AID199806
Retinoic acid receptor RXR-gammaHomo sapiens (human)Ki0.01860.00140.15261.0000AID199368; AID199966
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.02100.00000.338510.0000AID438596
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Cytochrome P450 26B1Homo sapiens (human)IC50 (µMol)5.90000.00051.97285.9000AID1290555
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor alphaHomo sapiens (human)EC50 (µMol)6.66870.00020.17902.5119AID1454787; AID198035; AID200112
Retinoic acid receptor alphaHomo sapiens (human)Kd1.00000.00020.52689.5000AID200133
Retinoic acid receptor betaHomo sapiens (human)EC50 (µMol)6.76070.00030.23116.9000AID1454788; AID198525; AID199384
Retinoic acid receptor betaHomo sapiens (human)Kd1.00000.00020.28762.3000AID199385
Retinoic acid receptor gamma Homo sapiens (human)EC50 (µMol)6.88270.00020.06130.6480AID1454789; AID199036; AID199389
Retinoic acid receptor gamma Homo sapiens (human)Kd1.00000.00020.42453.8240AID199390
Retinoic acid receptor RXR-alphaHomo sapiens (human)EC50 (µMol)0.03900.00010.34279.1000AID1152429; AID1205893; AID1250616; AID1286831; AID1286833; AID1286835; AID1413162; AID1454759; AID1614972; AID1615901; AID1630288; AID1633899; AID199198; AID199353; AID199632; AID199633; AID438595; AID501476; AID569829; AID581601; AID755628
Retinoic acid receptor RXR-alphaHomo sapiens (human)Kd0.26910.00040.58388.8000AID1062028; AID1152428; AID1152431; AID1250622; AID1614935; AID167585; AID1799444; AID199208; AID199490
Retinoic acid receptor RXR-alphaMus musculus (house mouse)EC50 (µMol)0.04000.04001.71805.0000AID420858
Retinoic acid receptor RXR-betaHomo sapiens (human)EC50 (µMol)0.04350.00080.52545.2000AID1413163; AID1454760; AID1614973; AID1630288; AID199801; AID199802
Retinoic acid receptor RXR-betaMus musculus (house mouse)EC50 (µMol)0.02450.00300.27821.2110AID199356; AID199787
Retinoic acid receptor RXR-betaMus musculus (house mouse)Kd0.02100.00300.19691.0000AID199357; AID199793
Retinoic acid receptor RXR-gammaMus musculus (house mouse)EC50 (µMol)0.02250.00400.19000.9610AID199372; AID199946
Retinoic acid receptor RXR-gammaMus musculus (house mouse)Kd0.02900.00300.08300.3500AID199374; AID199952
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)Kd0.03600.00010.03790.1995AID167585
Nuclear receptor subfamily 4 group A member 2Homo sapiens (human)EC50 (µMol)0.01000.01002.89125.1000AID1286833
Retinoic acid receptor RXR-gammaHomo sapiens (human)EC50 (µMol)0.04480.00010.23801.2250AID1413164; AID1454761; AID1614974; AID1630288; AID199960; AID199961
Type-2 angiotensin II receptorHomo sapiens (human)Kd0.03600.00250.02540.0500AID167585
Oxysterols receptor LXR-betaHomo sapiens (human)EC50 (µMol)0.43400.00010.40077.3000AID1480571
Retinoic acid receptor RXR-alphaRattus norvegicus (Norway rat)EC50 (µMol)0.04000.01100.25020.8200AID1062027
Oxysterols receptor LXR-alphaHomo sapiens (human)EC50 (µMol)0.19600.00010.63026.7100AID1480570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor RXR-alphaHomo sapiens (human)Activity3.74003.45003.59503.7400AID1907712
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (416)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
kidney developmentCytochrome P450 26A1Homo sapiens (human)
vitamin metabolic processCytochrome P450 26A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 26A1Homo sapiens (human)
response to retinoic acidCytochrome P450 26A1Homo sapiens (human)
response to vitamin ACytochrome P450 26A1Homo sapiens (human)
retinoic acid catabolic processCytochrome P450 26A1Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 26A1Homo sapiens (human)
negative regulation of retinoic acid receptor signaling pathwayCytochrome P450 26A1Homo sapiens (human)
sterol metabolic processCytochrome P450 26A1Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
ureteric bud developmentRetinoic acid receptor alphaHomo sapiens (human)
neural tube closureRetinoic acid receptor alphaHomo sapiens (human)
liver developmentRetinoic acid receptor alphaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor alphaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
protein phosphorylationRetinoic acid receptor alphaHomo sapiens (human)
germ cell developmentRetinoic acid receptor alphaHomo sapiens (human)
female pregnancyRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of translationRetinoic acid receptor alphaHomo sapiens (human)
hippocampus developmentRetinoic acid receptor alphaHomo sapiens (human)
prostate gland developmentRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of granulocyte differentiationRetinoic acid receptor alphaHomo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor alphaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor alphaHomo sapiens (human)
response to estradiolRetinoic acid receptor alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of type II interferon productionRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of tumor necrosis factor productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-13 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-4 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-5 productionRetinoic acid receptor alphaHomo sapiens (human)
response to vitamin ARetinoic acid receptor alphaHomo sapiens (human)
response to cytokineRetinoic acid receptor alphaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of apoptotic processRetinoic acid receptor alphaHomo sapiens (human)
apoptotic cell clearanceRetinoic acid receptor alphaHomo sapiens (human)
response to ethanolRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of neuron differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell cycleRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of synaptic plasticityRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of bindingRetinoic acid receptor alphaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
Sertoli cell fate commitmentRetinoic acid receptor alphaHomo sapiens (human)
limb developmentRetinoic acid receptor alphaHomo sapiens (human)
face developmentRetinoic acid receptor alphaHomo sapiens (human)
trachea cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
chondroblast differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
cellular response to lipopolysaccharideRetinoic acid receptor alphaHomo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
cellular response to estrogen stimulusRetinoic acid receptor alphaHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionRetinoic acid receptor alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
ureteric bud developmentRetinoic acid receptor betaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor betaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor betaHomo sapiens (human)
apoptotic processRetinoic acid receptor betaHomo sapiens (human)
signal transductionRetinoic acid receptor betaHomo sapiens (human)
striatum developmentRetinoic acid receptor betaHomo sapiens (human)
neurogenesisRetinoic acid receptor betaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor betaHomo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor betaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor betaHomo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor betaHomo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor betaHomo sapiens (human)
embryonic digestive tract developmentRetinoic acid receptor betaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor betaHomo sapiens (human)
neural precursor cell proliferationRetinoic acid receptor betaHomo sapiens (human)
stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
cell differentiationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
neural tube closureRetinoic acid receptor gamma Homo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor gamma Homo sapiens (human)
growth plate cartilage chondrocyte growthRetinoic acid receptor gamma Homo sapiens (human)
apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
regulation of cell sizeRetinoic acid receptor gamma Homo sapiens (human)
anterior/posterior pattern specificationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of gene expressionRetinoic acid receptor gamma Homo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor gamma Homo sapiens (human)
regulation of myelinationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor gamma Homo sapiens (human)
response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
multicellular organism growthRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of programmed cell deathRetinoic acid receptor gamma Homo sapiens (human)
regulation of myeloid cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
canonical Wnt signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
face developmentRetinoic acid receptor gamma Homo sapiens (human)
trachea cartilage developmentRetinoic acid receptor gamma Homo sapiens (human)
prostate gland epithelium morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
Harderian gland developmentRetinoic acid receptor gamma Homo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cellular response to leukemia inhibitory factorRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-betaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to hypoxiaNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron migrationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-templated transcriptionNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
adult locomotory behaviorNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
post-embryonic developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system projection neuron axonogenesisNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
habenula developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to oxidative stressNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of dopamine metabolic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopamine biosynthetic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron maturationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of respiratory gaseous exchangeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
general adaptation syndromeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
canonical Wnt signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
midbrain dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-gammaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-gammaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-gammaHomo sapiens (human)
blood vessel remodelingType-2 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by circulatory renin-angiotensinType-2 angiotensin II receptorHomo sapiens (human)
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressureType-2 angiotensin II receptorHomo sapiens (human)
brain renin-angiotensin systemType-2 angiotensin II receptorHomo sapiens (human)
cell surface receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messengerType-2 angiotensin II receptorHomo sapiens (human)
brain developmentType-2 angiotensin II receptorHomo sapiens (human)
regulation of blood pressureType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of heart rateType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of cell growthType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityType-2 angiotensin II receptorHomo sapiens (human)
regulation of metanephros sizeType-2 angiotensin II receptorHomo sapiens (human)
exploration behaviorType-2 angiotensin II receptorHomo sapiens (human)
nitric oxide-cGMP-mediated signalingType-2 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
vasodilationType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of neurotrophin TRK receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
neuron apoptotic processType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of metanephric glomerulus developmentType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesisType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-2 angiotensin II receptorHomo sapiens (human)
hormone-mediated signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of triglyceride biosynthetic processOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of cholesterol effluxOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of lipid storageOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of cholesterol storageOxysterols receptor LXR-betaHomo sapiens (human)
intracellular receptor signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of lipid transportOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of cholesterol transportOxysterols receptor LXR-betaHomo sapiens (human)
phosphatidylcholine acyl-chain remodelingOxysterols receptor LXR-betaHomo sapiens (human)
cholesterol homeostasisOxysterols receptor LXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of fatty acid biosynthetic processOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of proteolysisOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of DNA-templated transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of pinocytosisOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of lipoprotein lipase activityOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of protein metabolic processOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of high-density lipoprotein particle assemblyOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of pancreatic juice secretionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of secretion of lysosomal enzymesOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of cold-induced thermogenesisOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of miRNA transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressOxysterols receptor LXR-betaHomo sapiens (human)
cell differentiationOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIOxysterols receptor LXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of triglyceride biosynthetic processOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of cholesterol effluxOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of cholesterol storageOxysterols receptor LXR-alphaHomo sapiens (human)
intracellular receptor signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of lipid transportOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of cholesterol transportOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of transporter activityOxysterols receptor LXR-alphaHomo sapiens (human)
response to progesteroneOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
phosphatidylcholine acyl-chain remodelingOxysterols receptor LXR-alphaHomo sapiens (human)
cholesterol homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
regulation of circadian rhythmOxysterols receptor LXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of macrophage activationOxysterols receptor LXR-alphaHomo sapiens (human)
apoptotic cell clearanceOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of fatty acid biosynthetic processOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of proteolysisOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of pinocytosisOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of inflammatory responseOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of lipoprotein lipase activityOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of protein metabolic processOxysterols receptor LXR-alphaHomo sapiens (human)
lipid homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
sterol homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
triglyceride homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
cellular response to lipopolysaccharideOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of pancreatic juice secretionOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of secretion of lysosomal enzymesOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of cold-induced thermogenesisOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressOxysterols receptor LXR-alphaHomo sapiens (human)
cell differentiationOxysterols receptor LXR-alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
cell fate determinationCytochrome P450 26B1Homo sapiens (human)
establishment of T cell polarityCytochrome P450 26B1Homo sapiens (human)
kidney developmentCytochrome P450 26B1Homo sapiens (human)
vitamin metabolic processCytochrome P450 26B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 26B1Homo sapiens (human)
inflammatory responseCytochrome P450 26B1Homo sapiens (human)
male meiotic nuclear divisionCytochrome P450 26B1Homo sapiens (human)
spermatogenesisCytochrome P450 26B1Homo sapiens (human)
proximal/distal pattern formationCytochrome P450 26B1Homo sapiens (human)
positive regulation of gene expressionCytochrome P450 26B1Homo sapiens (human)
embryonic limb morphogenesisCytochrome P450 26B1Homo sapiens (human)
response to vitamin ACytochrome P450 26B1Homo sapiens (human)
retinoic acid catabolic processCytochrome P450 26B1Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 26B1Homo sapiens (human)
tongue morphogenesisCytochrome P450 26B1Homo sapiens (human)
regulation of T cell differentiationCytochrome P450 26B1Homo sapiens (human)
retinoic acid receptor signaling pathwayCytochrome P450 26B1Homo sapiens (human)
negative regulation of retinoic acid receptor signaling pathwayCytochrome P450 26B1Homo sapiens (human)
bone morphogenesisCytochrome P450 26B1Homo sapiens (human)
establishment of skin barrierCytochrome P450 26B1Homo sapiens (human)
cornificationCytochrome P450 26B1Homo sapiens (human)
cellular response to retinoic acidCytochrome P450 26B1Homo sapiens (human)
positive regulation of tongue muscle cell differentiationCytochrome P450 26B1Homo sapiens (human)
sterol metabolic processCytochrome P450 26B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (139)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
retinoic acid bindingCytochrome P450 26A1Homo sapiens (human)
iron ion bindingCytochrome P450 26A1Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 26A1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 26A1Homo sapiens (human)
oxygen bindingCytochrome P450 26A1Homo sapiens (human)
heme bindingCytochrome P450 26A1Homo sapiens (human)
all-trans retinoic acid 4-hydrolase activityCytochrome P450 26A1Homo sapiens (human)
all-trans retinoic acid 18-hydroxylase activityCytochrome P450 26A1Homo sapiens (human)
monooxygenase activityCytochrome P450 26A1Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
mRNA regulatory element binding translation repressor activityRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activityRetinoic acid receptor alphaHomo sapiens (human)
transcription coactivator bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor alphaHomo sapiens (human)
signaling receptor bindingRetinoic acid receptor alphaHomo sapiens (human)
protein bindingRetinoic acid receptor alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor alphaHomo sapiens (human)
protein domain specific bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
histone deacetylase bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase B bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor alphaHomo sapiens (human)
mRNA 5'-UTR bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase A bindingRetinoic acid receptor alphaHomo sapiens (human)
alpha-actinin bindingRetinoic acid receptor alphaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor betaHomo sapiens (human)
DNA bindingRetinoic acid receptor betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor betaHomo sapiens (human)
protein-containing complex bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor betaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor gamma Homo sapiens (human)
DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
chromatin bindingRetinoic acid receptor gamma Homo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor gamma Homo sapiens (human)
protein bindingRetinoic acid receptor gamma Homo sapiens (human)
zinc ion bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor gamma Homo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear receptor activityRetinoic acid receptor gamma Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
beta-catenin bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
molecular condensate scaffold activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
angiotensin type II receptor activityType-2 angiotensin II receptorHomo sapiens (human)
protein bindingType-2 angiotensin II receptorHomo sapiens (human)
receptor antagonist activityType-2 angiotensin II receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificOxysterols receptor LXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificOxysterols receptor LXR-betaHomo sapiens (human)
DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
protein bindingOxysterols receptor LXR-betaHomo sapiens (human)
zinc ion bindingOxysterols receptor LXR-betaHomo sapiens (human)
chromatin DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
apolipoprotein A-I receptor bindingOxysterols receptor LXR-betaHomo sapiens (human)
nuclear retinoid X receptor bindingOxysterols receptor LXR-betaHomo sapiens (human)
ATPase bindingOxysterols receptor LXR-betaHomo sapiens (human)
nuclear receptor activityOxysterols receptor LXR-betaHomo sapiens (human)
transcription cis-regulatory region bindingOxysterols receptor LXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingOxysterols receptor LXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificOxysterols receptor LXR-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificOxysterols receptor LXR-alphaHomo sapiens (human)
DNA bindingOxysterols receptor LXR-alphaHomo sapiens (human)
nuclear receptor activityOxysterols receptor LXR-alphaHomo sapiens (human)
protein bindingOxysterols receptor LXR-alphaHomo sapiens (human)
zinc ion bindingOxysterols receptor LXR-alphaHomo sapiens (human)
cholesterol bindingOxysterols receptor LXR-alphaHomo sapiens (human)
chromatin DNA bindingOxysterols receptor LXR-alphaHomo sapiens (human)
sterol response element bindingOxysterols receptor LXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingOxysterols receptor LXR-alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
retinoic acid bindingCytochrome P450 26B1Homo sapiens (human)
iron ion bindingCytochrome P450 26B1Homo sapiens (human)
protein bindingCytochrome P450 26B1Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 26B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 26B1Homo sapiens (human)
heme bindingCytochrome P450 26B1Homo sapiens (human)
all-trans retinoic acid 18-hydroxylase activityCytochrome P450 26B1Homo sapiens (human)
monooxygenase activityCytochrome P450 26B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 26A1Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
nucleolusRetinoic acid receptor alphaHomo sapiens (human)
cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
cytosolRetinoic acid receptor alphaHomo sapiens (human)
plasma membraneRetinoic acid receptor alphaHomo sapiens (human)
actin cytoskeletonRetinoic acid receptor alphaHomo sapiens (human)
dendriteRetinoic acid receptor alphaHomo sapiens (human)
perinuclear region of cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
chromatinRetinoic acid receptor alphaHomo sapiens (human)
protein-containing complexRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor betaHomo sapiens (human)
cytoplasmRetinoic acid receptor betaHomo sapiens (human)
chromatinRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleoplasmRetinoic acid receptor gamma Homo sapiens (human)
cytoplasmRetinoic acid receptor gamma Homo sapiens (human)
membraneRetinoic acid receptor gamma Homo sapiens (human)
chromatinRetinoic acid receptor gamma Homo sapiens (human)
transcription regulator complexRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaMus musculus (house mouse)
nucleusRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleolusRetinoic acid receptor RXR-betaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-betaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear speckNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein-containing complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
cytoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-gammaHomo sapiens (human)
plasma membraneType-2 angiotensin II receptorHomo sapiens (human)
plasma membraneType-2 angiotensin II receptorHomo sapiens (human)
nucleusOxysterols receptor LXR-betaHomo sapiens (human)
nucleoplasmOxysterols receptor LXR-betaHomo sapiens (human)
cytoplasmOxysterols receptor LXR-betaHomo sapiens (human)
cytosolOxysterols receptor LXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexOxysterols receptor LXR-betaHomo sapiens (human)
chromatinOxysterols receptor LXR-betaHomo sapiens (human)
nucleusOxysterols receptor LXR-betaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusOxysterols receptor LXR-alphaHomo sapiens (human)
nucleoplasmOxysterols receptor LXR-alphaHomo sapiens (human)
cytoplasmOxysterols receptor LXR-alphaHomo sapiens (human)
cytosolOxysterols receptor LXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexOxysterols receptor LXR-alphaHomo sapiens (human)
chromatinOxysterols receptor LXR-alphaHomo sapiens (human)
receptor complexOxysterols receptor LXR-alphaHomo sapiens (human)
nucleusOxysterols receptor LXR-alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
cytoplasmCytochrome P450 26B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 26B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (368)

Assay IDTitleYearJournalArticle
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1630288Agonist activity at human RXR binding domain and activation domain expressed in human HCT116 cells assessed as rexinoid activity incubated for 24 hrs by luciferase reporter gene based mammalian two-hybrid assay2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-
AID1152431Agonist activity at human RXR-alpha-ligand binding domain homodimers assessed as coactivator recruitment by measuring GRIP1 binding to receptor by isothermal titration calorimetry2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID581601Agonist activity at RXRalpha transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
AID81987Compound was examined for its ability to induce apoptosis on HL-60 cell line2002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Synthesis of new Targretin analogues that induce apoptosis in leukemia HL-60 cells.
AID581604Agonist activity at LXRalpha transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
AID581602Agonist activity at RXRalpha transfected in human COS1 cells at 1 uM after 18 hrs by luciferase reporter gene transactivation assay relative to LGD10692010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
AID198035Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1738917Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1370652Induction of apoptosis in human MCF10A cells assessed as ratio of cleaved caspase-3 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1710500Binding affinity to human RXRalpha-LBD (224 to 462 residues) expressed in Escherichia coli BL21(DE3) incubated for 1 hr in presence of compound by [3H]9-Cis retinoic acid assay2021ACS medicinal chemistry letters, Jun-10, Volume: 12, Issue:6
Creation of Fluorescent RXR Antagonists Based on CBTF-EE and Application to a Fluorescence Polarization Binding Assay.
AID1370647Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1744020Binding affinity to human RXR-alpha assessed as induction of conformational changes by measuring theta222/theta208 ratio at 15 uM incubated for 2 hrs by CD spectroscopy2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
AID1180623Activation of LXR in mouse C2C12 cells assessed as induction of lipoprotein lipase mRNA expression at 1 uM after 24 hrs by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1665608AUC (0.5 to 6 hrs) in C57BL/6 mouse brain at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID1744024Agonist activity at RXR-alpha in mouse RAW264.7 cells assessed as inhibition of LPS-induced suppressed Nos2 gene expression at 0.1 uM incubated for 6 hrs by RT-PCR analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
AID1370645Cytotoxicity against human BT549 cells assessed as reduction in cell viability at 5 uM by MTT assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1413164Agonist activity at human RXRgamma expressed in African green monkey CV1 cells2018MedChemComm, Aug-01, Volume: 9, Issue:8
Scaffold hopping from synthetic RXR modulators by virtual screening and
AID199960Effective concentrations against Retinoic acid receptor RXR-gamma1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1370682Inhibition of mammosphere formation in human MCF7 cells assessed as ratio of Sox2 to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1537534Agonist activity at RXR in human HepG2 cells assessed as induction of ANGPTL4 mRNA expression at 1 uM after 8 hrs by RT-PCR analysis2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
AID499581Activation of RXR/LXR heterodimer in mouse RAW264.7 cells assessed as induction of ABCA1 mRNA expression by RT-PCR2010Journal of natural products, Aug-27, Volume: 73, Issue:8
Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor.
AID1286835Agonist activity at Renilla luciferase/GFP2-tagged RXRalpha homodimer (unknown origin) expressed in HEK293T cells by BRET2 assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor-Nuclear Receptor Related 1 Protein Dimer Activation.
AID1250616Agonist activity at RXRalpha LBD (unknown origin) expressed in CV1 cells2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.
AID199389Effective concentration against retinoid receptor isoform (RAR gamma) expressed in CV-1 cells1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1370695Effect on beta-catenin translocation in nuclear fraction of human MDA-MB-231 cells assessed as ratio of beta-catenin to beta-actin level at 10 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199372Effective concentration against retinoid receptor isoform (RXR gamma) expressed in CV-1 cells1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1370681Inhibition of mammosphere formation in human MCF7 cells assessed as ratio of Oct4A to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID198525Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1370680Inhibition of mammosphere formation in human MCF7 cells assessed as ratio of Nanog to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199490Ability to bind directly to Retinoic acid receptor RXR-alpha was evaluated in a competitive binding assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID438595Agonist activity at human recombinant Gal4-tagged RXRalpha expressed in human Caco-2 cells assessed as receptor homodimerization after 24 hrs by mammalian two hybrid assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID200112Effective concentration against retinoid receptor isoform (RAR alpha) expressed in CV-1 cells1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1512022Solubility of compound at 3 mg after 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.
AID1480571Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID1738923Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human FaDu cells incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1738915Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1152429Agonist activity at Gal4-fused human RXR-alpha expressed in HEK293 cells assessed as receptor-mediated transcriptional activity treated 24 hrs after transfection measured 48 hrs post-transfection by dual luciferase reporter assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
AID1370644Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 5 uM by MTT assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID730296Partial agonist activity at human RXRalpha expressed in Escherichia coli BL21AI assessed as decrease in recruitment of fluorescent-labeled corepressor SMRT-ID2 at 10 uM after 1 hr by fluorescence polarization assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID725918Agonist activity at RXR (unknown origin) expressed in human HCT116 cells co-expressing RXRE at 20 to 40 uM after 24 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Synthesis and biological evaluation of halogenated curcumin analogs as potential nuclear receptor selective agonists.
AID438596Displacement of [3H]9-cis-retinoic acid form human RXRalpha expressed in human Caco-2 cells after 16 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID1370650Induction of apoptosis in human MDA-MB-231 cells assessed as ratio of cleaved caspase-3 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID81833Concentration of a compound which induces HL-60 cell differentiation to the extent of 50% in the presence of 3.0 x10 e-10 M Am801997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1633900Agonist activity at human RXRalpha expressed in African green monkey COS1 cells harboring CRBP2-tk-luc reporter incubated for 18 hrs by steady-glo luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1370651Induction of apoptosis in human BT549 cells assessed as ratio of cleaved caspase-3 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1180654Activation of LXR in mouse C2C12 cells assessed as induction of ABCA1 mRNA expression at 1 uM after 24 hrs in presence of T0901317 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID755621Cytotoxicity against human GBC-SD cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID438601Mutagenic activity in Saccharomyces cerevisiae after 3 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID1454789Agonist activity at RARgamma (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1370691Effect on epithelial-mesenchymal transition in human BT549 cells assessed as ratio of vimentin to beta-actin level at 5 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID702977Cytotoxicity against african green monkey COS1 cells assessed as cell survival at 40 uM relative to control2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
AID1615902Displacement of 9-cis-[11,12-3H]-retinoic acid from human RXRalpha LBD incubated for overnight by scintillation counting method2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
AID199229Percent maximal induction of human RXR-beta receptor relative to 9-cis-RA1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID702945Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 1.25 to 20 uM after 4 to 6 hrs by luciferase reporter gene assay relative to control2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
AID499576Agonist activity at RXRalpha in HEK293 cells assessed as transcriptional activation after 48 hrs by luciferase reporter gene assay in presence of RXR antagonist PA4522010Journal of natural products, Aug-27, Volume: 73, Issue:8
Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor.
AID1180610Activation of RXR/LXR heterodimer in mouse RAW264.7 cells assessed as potentiation of T0901317-induced increase in ABCA1 mRNA level at 1 uM by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1630297Agonist activity at human RARalpha expressed in HEK293 cells assessed as increase in RARE-mediated transcription at 100 nM incubated for 24 hrs by RARE luciferase reporter gene assay relative to all-trans-retinoic acid2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-
AID1180658Activation of PPARdelta in mouse C2C12 cells assessed as induction of FABP3 mRNA expression at 1 uM after 24 hrs by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1537507Cytotoxicity against human HepG2 cells up to 100 uM after 48 hrs by WST1 assay2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
AID1370692Effect on epithelial-mesenchymal transition in human BT549 cells assessed as ratio of slug to beta-actin level at 5 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1370686Inhibition of mammosphere formation in human BT549 cells assessed as ratio of KLF4 to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1370693Effect on beta-catenin translocation in cytosolic fraction of human MDA-MB-231 cells assessed as ratio of beta-catenin to beta-actin level at 10 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1614943Activation of LXR in human HepG2 cells assessed as increase in SREBP-1c mRNA expression at 1 uM after 12 hrs followed by renewal of medium containing test compounds after 6 hrs by PCR analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID199207Percent maximal induction of human RXR-alpha receptor relative to 9-cis-RA1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID438419Agonist activity at human recombinant Gal4-tagged RXRalpha expressed in human Caco-2 cells assessed as receptor homodimerization at 100 nM after 24 hrs by mammalian two hybrid assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID1738922Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human A2780 cells incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1180604Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal at 0.1 uM after 24 to 48 hrs by luciferase reporter gene assay in presence of PA452 pan-antagonist2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID199390Tested for binding affinity against [3H]-ATRA binding to retinoid receptor isoform (RAR gamma) expressed in baculovirus1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1370646Cytotoxicity against human MCF10A cells assessed as reduction in cell viability at 5 uM by MTT assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1633892Toxicity in fertilized zebra fish embryos assessed as survival rate at 100 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1480580Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells at 10 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay relative to T09013172017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID755617Cytotoxicity against bexarotene-resistant human KB cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1775931Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.
AID199639Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-alpha in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1614935Binding affinity to recombinant RXRalpha (unknown origin) by isothermal titration calorimetry2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1615905Displacement of CU-6PMN from human RXRalpha LBD incubated for 2 hrs by fluorescence based assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
AID1355460Transactivation of RXR in human HepG2 cells assessed as induction of apoE mRNA expression at 1 uM after 8 hrs by qRT-PCR analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics.
AID199198Effective concentration against retinoid receptor isoform (RXR alpha) expressed in CV-1 cells1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID167584Transcriptional activation of Retinoic acid receptor RXR-alpha2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Synthesis and characterization of a new RXR agonist based on the 6-tert-butyl-1,1-dimethylindanyl structure.
AID1614972Agonist activity RXRalpha (unknown origin)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID199356Effective concentration against retinoid receptor isoform (RXR beta) expressed in CV-1 cells1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID199213Selective activity towards retinoid X receptor-alpha1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1205895Agonist activity at RXRalpha (unknown origin) expressed in COS1 cells incubated for 18 hrs by luciferase reporter gene assay relative to untrated control2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
AID1370663Induction of apoptosis in nuclear fractions of human MDA-MB-231 cells assessed as ratio of cleaved PARP to beta-actin level at 10 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID199966Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-gamma in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1454787Agonist activity at RARaplha (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID199632Effective concentration against Retinoic acid receptor RXR-alpha1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID199952Binding affinity to Retinoic acid receptor RXR-gamma was evaluated in a competitive binding assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID1062016Antitumor activity against BRDU-labeled Sprague-Dawley rat mammary tumor cells assessed as reduction in proliferation index at 150 mg/kg, po administered with diet after 7 days relative to control2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID755618Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1633896Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 100 nM after 120 hrs post fertilization by microscopic method relative to control2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1454760Agonist activity at RXRbeta (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1180649Activation of RXR/VDR heterodimer in human hepatoma cells assessed as increase in CYP24A1 mRNA level at 1 uM in presence of VDR agonist calcitriol by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1512042Agonist activity at full-length human PPARgamma/RXR expressed in HEK293T cells at 0.3 uM after 14 to 16 hrs in presence of 1 uM rosiglitazone by dual-glo luciferase reporter gene assay relative to rosiglitazone2019ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.
AID199232Selective activity towards retinoid X receptor-beta1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1665619AUC (0.5 to 6 hrs) in C57BL/6 mouse serum at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID1180655Activation of LXR in mouse C2C12 cells assessed as induction of ApoE mRNA expression at 1 uM after 24 hrs in presence of T0901317 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1630304Inhibition of HDAC1 gene expression in human HUT78 cells at 100 nM incubated for 48 hrs by quantitative real-time PCR method2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-
AID1630305Mutagenicity in Saccharomyces cerevisiae D7 assessed as induction of mutagenesis by measuring forward and reverse mutations up to 0.1 mg/mL2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-
AID1180651Activation of LXR in mouse C2C12 cells assessed as induction of SREBP1 mRNA expression at 1 uM after 24 hrs in presence of T0901317 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1180618Activation of RXR/VDR heterodimer in human hepatoma cells assessed as increase in CYP24A1 mRNA level at 1 uM by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1062014Toxicity in 50 days old Sprague-Dawley rat assessed as increase in serum triglyceride level relative to control2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID199625Relative activity against Retinoic acid receptor RXR-alpha at 10e-6 M retinoid relative to 10e-6 M of 9-cis-RA.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1290555Inhibition of microsomal fraction of human CYP26B1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by HPLC analysis in presence of rat P450 reductase2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
AID1370690Effect on epithelial-mesenchymal transition in human BT549 cells assessed as ratio of E-cadherin to beta-actin level at 5 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1710499Binding affinity to human RXRalpha-LBD (224 to 462 residues) expressed in Escherichia coli BL21(DE3) incubated for 1 hr in presence of compound by fluorescence polarization assay2021ACS medicinal chemistry letters, Jun-10, Volume: 12, Issue:6
Creation of Fluorescent RXR Antagonists Based on CBTF-EE and Application to a Fluorescence Polarization Binding Assay.
AID1633893Toxicity in fertilized zebra fish embryos assessed as survival rate at 287 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1205917Ratio of drug level in brain to plasma of ICR mouse at 30 mg/kg, po administered as single dose measured after 1 hr2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
AID1370701Effect on beta-catenin translocation in nuclear fraction of human BT549 cells assessed as ratio of beta-catenin to beta-actin level at 10 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1614973Agonist activity RXRbeta (unknown origin)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID438599Cytotoxicity against human HUT78 cells assessed as LDH release at 100 nM after 24 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID1512037Agonist activity at full-length human RXR/LXR expressed in HEK293T cells at 0.3 uM after 14 to 16 hrs in presence of 1 uM T0901317 by dual-glo luciferase reporter gene assay relative to T09013172019ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.
AID198372Relative activity against Retinoic acid receptor beta at 10e-6 M with respect to 10e-6 M of trans-RA1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1370666Inhibition of colony formation in human MCF7 cells at 5 uM supplemented with fresh medium containing compound every 3 to 4 days for 7 days by crystal violet staining based adherent cell colony-forming assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1180624Activation of LXR in mouse C2C12 cells assessed as induction of lipoprotein lipase mRNA expression at 1 uM after 24 hrs in presence of T0901317 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1614936Binding affinity to recombinant PPARgamma (unknown origin) by isothermal titration calorimetry2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID200141Selective activity towards retinoic acid receptor-alpha1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1370688Effect on epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as ratio of vimentin to beta-actin level at 5 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1062015Antitumor activity against Sprague-Dawley rat mammary tumor cells assessed as increase in apoptotic index at 150 mg/kg, po administered with diet after 7 days by TUNEL assay relative to control2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID200133Inhibition of [3H]-ATRA binding to baculovirus expressed retinoid receptor RAR alpha1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1370697Induction of apoptosis in nuclear fractions of human MDA-MB-231 cells assessed as ratio of PARP to beta-actin level at 10 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199374Inhibition of [3H]9-cis-RA binding to baculovirus expressed retinoid receptor RXR gamma1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID501476Agonist activity at RXRalpha by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1370668Inhibition of colony formation in human MDA-MB-231 cells at 10 uM supplemented with fresh medium containing compound every 3 days for 10 days by microscopic method based soft agar colony formation assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1454759Agonist activity at RXRaplha (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID199036Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1180616Activation of RXR/RAR heterodimer in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 1 uM by quantitative RT-PCR analysis in presence of atRA2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1738921Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human MCF7 cells incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1370656Induction of apoptosis in human MCF10A cells assessed as ratio of cleaved caspase-8 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1480570Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID199216Relative EC30 for human RXR-alpha receptor as EC30(compound) divided EC30(9-cis-RA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1370655Induction of apoptosis in human BT549 cells assessed as ratio of cleaved caspase-8 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1250622Binding affinity to human RXRalpha LBD after 15 mins by isothermal titration calorimetry assay2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.
AID1630302Agonist activity at RXR in human HepG2 cells assessed as induction of CYP3A4 expression at 100 nM incubated for 24 hrs by quantitative real-time PCR method relative to untreated control2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-
AID167585Dissociation constant for binding to Retinoic acid receptor RXR-alpha2002Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18
Synthesis and characterization of a new RXR agonist based on the 6-tert-butyl-1,1-dimethylindanyl structure.
AID1907712Displacement of CBTF-BODIPY from RXR-alpha LBD (unknown origin) at 0.03125 to 32 uM incubated for 1 hr by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
AID199802Transcriptional activity was evaluated in CV-1 cells transfected with expression vector for Retinoic acid receptor RXR-beta1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1480568Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 10 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay relative to T09013172017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID1480575Agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 1 uM in presence of LXR-agonist 22(R)-hydroxycholesterol measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID1180653Activation of LXR in mouse C2C12 cells assessed as induction of ApoD mRNA expression at 1 uM after 24 hrs in presence of T0901317 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1370660Induction of apoptosis in human MCF10A cells assessed as ratio of cleaved caspase-9 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID197918Relative activity against Retinoic acid receptor alpha at 10e-6 M with respect to 10e-6 M of trans-RA1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1152432Agonist activity at RXR-alpha in rat R3KE cells infected with oncogene KLF4-ER assessed as inhibition of KLF4-mediated oncogenic transformation2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
AID702948Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 1.25 to 20 uM after 25 hrs by luciferase reporter gene assay relative to control2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
AID1454761Agonist activity at RXRgamma (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID702952Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 50 uM after 12 hrs by luciferase reporter gene assay relative to control2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID730297Partial agonist activity at human RXRalpha expressed in Escherichia coli BL21AI assessed as recruitment of fluorescent-labeled coactivator D22 at 10 uM after 1 hr by fluorescence polarization assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID199371Relative EC30 for human RXR-gamma receptor as EC30(compound) divided by EC30(9-cis-RA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID199793Binding affinity to Retinoic acid receptor RXR-beta was determined in a competitive binding assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID1370658Induction of apoptosis in human MDA-MB-231 cells assessed as ratio of cleaved caspase-9 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1370689Effect on epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as ratio of slug to beta-actin level at 5 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1370643Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 5 uM by MTT assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1738918Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1738919Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human A375 cells incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1062028Binding affinity to human RXRalpha ligand binding domain by fluorescence assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID772977Agonist activity at human RXR-alpha transfected in african green monkey COS-1 cells at 50 uM by dual-luciferase reporter gene assay relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Chemopreventive and antioxidant activity of 6-substituted imidazo[2,1-b]thiazoles.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1152433Induction of hyperlipidemia in N-methylnitrosurea-induced mammary cancer Sprague-Dawley rat model assessed as increase in serum triglyceride level at 150 mg/kg administered through diet for 7 days2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
AID1480579Cmax in patient with solid tumor at 300 mg/m2, po administered once daily2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID199355Relative EC30 for human RXR-beta receptor as EC30(compound) divided by EC30(9-cis-RA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1413162Agonist activity at human RXRalpha expressed in African green monkey CV1 cells2018MedChemComm, Aug-01, Volume: 9, Issue:8
Scaffold hopping from synthetic RXR modulators by virtual screening and
AID1633899Agonist activity at human RXRalpha expressed in African green monkey COS1 cells harboring CRBP2-tk-luc reporter incubated for 18 hrs by steady-glo luciferase reporter gene assay2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1180657Activation of PPARdelta in mouse C2C12 cells assessed as induction of ANGPTL4 mRNA expression at 1 uM after 24 hrs by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID199384Effective concentration against retinoid receptor isoform (RAR beta) expressed in CV-1 cells1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1738913Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID199357Inhibition of [3H]9-cis-RA binding to baculovirus expressed retinoid receptor RXR beta1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1480581Effect on recombinant firefly luciferase activity expressed in HEK293T cells at 1 uM after 12 to 14 hrs by luminescence assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID1205916Drug level in ICR mouse brain at 30 mg/kg, po administered as single dose measured after 1 hr2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
AID1370683Inhibition of mammosphere formation in human MDA-MB-231 cells assessed as ratio of C-Myc to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID569829Agonist activity at human RXRalpha LBD by cell based luciferase reporter gene assay2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.
AID198741Selective activity towards retinoic acid receptor-gamma1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1290556Inhibition of microsomal fraction of human CYP26A1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 1 min by HPLC analysis in presence of rat P450 reductase2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
AID1370648Cytotoxicity against human BT549 cells assessed as reduction in cell viability by MTT assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1286831Agonist activity at histidine-tagged ligand binding domain of human RXRalpha expressed in Escherichia coli BL21 (DE3) by luciferase reporter gene assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor-Nuclear Receptor Related 1 Protein Dimer Activation.
AID1370657Induction of apoptosis in human MCF7 cells assessed as ratio of cleaved caspase-8 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199806Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-beta in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1180614Activation of RXR/RAR heterodimer in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 1 uM by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID199961Transcriptional activity was evaluated in CV-1 cells transfected with expression vector for Retinoic acid receptor RXR-gamma1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1738914Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1370642Inhibition of mammosphere formation in human MCF7 cells assessed as ratio of C-Myc to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID198224Selective activity towards retinoic acid receptor-beta1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID199633Transcriptional activity was evaluated in CV-1 cells transfected with expression vector for Retinoic acid receptor RXR-alpha1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID198210Percent maximal induction of human RAR-beta receptor relative to ATRA1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1370685Inhibition of mammosphere formation in human BT549 cells assessed as ratio of C-Myc to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID197898Relative EC30 for human RAR-alpha receptor as EC30(compound) divided by EC30(ATRA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID198055Inhibition of [3H]ATRA binding to baculovirus expressed Retinoic acid receptor RAR alpha1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1896483Induction of triglyceride level in Sprague-Dawley rat at 150 mg/kg in diet for 7 days relative to control2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers.
AID1370665Induction of apoptosis in nuclear fractions of human BT549 cells assessed as ratio of cleaved PARP to beta-actin level at 10 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID755620Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID755628Transactivation of human RXRalpha transfected in human 293 cells after 48 hrs by dual-luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1370671Inhibition of mammosphere formation in human MCF7 cells at 10 uM after 7 days by microscopic method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1413163Agonist activity at human RXRbeta expressed in African green monkey CV1 cells2018MedChemComm, Aug-01, Volume: 9, Issue:8
Scaffold hopping from synthetic RXR modulators by virtual screening and
AID199217Relative IC50 for human RXR-alpha receptor as IC50(compound) divided by IC50(9-cis-RA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1537521Lipophilicity, log P of the compound by HPLC analysis2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
AID420858Transactivation of Gal4-LBD fused mouse RXRalpha (218 to 467) transfected in african green monkey CV1 cells assessed as luciferase activity at after 6 hrs by Dual-light chemiluminescent assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.
AID1180659Activation of PPARdelta in mouse C2C12 cells assessed as induction of CPT1A mRNA expression at 1 uM after 24 hrs by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1180622Activation of PPARgamma/RXR heterodimer in mouse 3T3-L1 cell assessed as induction of adipogenesis at 1 uM after 6 days by Oil red O-staining2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID499586Agonist activity at RXRalpha in mouse peritoneal macrophages assessed as ApoAI-mediated cholesterol efflux after 24 hrs by Western blotting2010Journal of natural products, Aug-27, Volume: 73, Issue:8
Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor.
AID1454788Agonist activity at RARbeta (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID581603Agonist activity at PPARgamma transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
AID1370699Effect on beta-catenin translocation in cytosolic fraction of human BT549 cells assessed as ratio of beta-catenin to beta-actin level at 10 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1205893Agonist activity at RXRalpha (unknown origin) expressed in COS1 cells incubated for 18 hrs by luciferase reporter gene assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
AID438597Agonist activity at human RARalpha expressed in human Caco-2 cells assessed as induction of RARE-mediated transcriptional activity at 100 nM after 24 hrs by luciferase reporter gene assay relative to all-trans retinoic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID198354Relative EC30 for human RAR-beta receptor as EC30(compound) divided by EC30(ATRA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID199787Ability to activate gene expression at Retinoic acid receptor RXR-beta was evaluated in a cotransfection assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID199385Inhibition of [3H]ATRA binding to baculovirus expressed retinoid receptor RAR beta1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1512027Agonist activity at full-length human RXR/LXR expressed in HEK293T cells at 0.3 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to untreated control2019ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.
AID200123Percent maximal induction of human RAR-alpha receptor relative to ATRA1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1370653Induction of apoptosis in human MCF7 cells assessed as ratio of cleaved caspase-3 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1370679Inhibition of mammosphere formation in human MCF7 cells assessed as ratio of KLF4 to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1633901Aqueous solubility in pH 7.4 PBS buffer at 1 mM after 6 hrs by HPLC analysis2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID199056Inhibition of [3H]-ATRA binding to baculovirus expressed Retinoic acid receptor RAR gamma1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1370654Induction of apoptosis in human MDA-MB-231 cells assessed as ratio of cleaved caspase-8 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199368Selective activity towards retinoid X receptor-gamma1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1775946Half life in po dosed rat2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.
AID198876Relative EC30 for human RAR-gamma receptor as EC30(compound) divided by EC30(ATRA)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1633888Toxicity in fertilized zebra fish embryos assessed as hatching rate at 100 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1614932Aqueous solubility of the compound in distilled water after 24 hrs by HPLC analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1062027Agonist activity at RXRalpha in rat RK3E cells assessed as transcriptional activation by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID1537520Aqueous solubility of the compound after 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
AID1180608Activation of RXR/LXR heterodimer in mouse RAW264.7 cells assessed as increase in ABCA1 mRNA level at 1 uM by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID199208Inhibition of [3H]9-cis-RA binding to baculovirus expressed retinoid receptor RXR alpha1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID198545Inhibition of [3H]ATRA binding to baculovirus expressed Retinoic acid receptor RAR beta1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID199365Percent maximal induction of human RXR-gamma receptor relative to 9-cis-RA1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1537533Agonist activity at RXR in human HepG2 cells assessed as induction of ADIPOQ mRNA expression at 1 uM after 8 hrs by RT-PCR analysis2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
AID1744021Agonist activity at RXR-alpha in mouse RAW264.7 cells assessed as inhibition of LPS-induced NF-kappaB transcription by measuring NF-kappaB level at 0.1 uM incubated for 24 hrs by SEAP dependent NF-kappaB reporter assay (Rvb = 1 No_unit)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
AID1205915Drug level in ICR mouse plasma at 30 mg/kg, po administered as single dose measured after 1 hr2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
AID1152435Anticancer activity against N-methylnitrosurea-induced mammary cancer in Sprague-Dawley rat assessed as decrease in proliferation index at 150 mg/kg administered through diet for 7 days by BrdU incorporation assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
AID1286833Agonist activity at Renilla luciferase/GFP2-tagged RXRalpha/Nurr1 (unknown origin) expressed in HEK293T cells by BRET2 assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor-Nuclear Receptor Related 1 Protein Dimer Activation.
AID198722Percent maximal induction of human RAR-gamma receptor relative to ATRA1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1370684Inhibition of mammosphere formation in human MDA-MB-231 cells assessed as ratio of KLF4 to beta actin level at 5 uM by Western blot analysis (Rvb= 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1775932Aqueous solubility of compound in pH 8 phosphate buffer incubated for 1 hr by HPLC analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.
AID725917Agonist activity at RAR (unknown origin) expressed in human HCT116 cells co-expressing RARE at 20 to 40 uM after 24 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Synthesis and biological evaluation of halogenated curcumin analogs as potential nuclear receptor selective agonists.
AID1180652Activation of LXR in mouse C2C12 cells assessed as induction of FAS mRNA expression at 1 uM after 24 hrs in presence of T0901317 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1180660Activation of PPARdelta in mouse C2C12 cells assessed as induction of FABP3 mRNA expression at 1 uM after 24 hrs in presence of GW501516 by quantitative RT-PCR analysis2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
AID1633889Toxicity in fertilized zebra fish embryos assessed as hatching rate at 287 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1370687Effect on epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as ratio of E-cadherin to beta-actin level at 5 uM by Western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1062024Inhibition of KLF4-ER-mediated rat RK3E cell transformation after 3 weeks2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID199801Effective concentrations against Retinoic acid receptor RXR-beta1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1370703Induction of apoptosis in nuclear fractions of human BT549 cells assessed as ratio of PARP to beta-actin level at 10 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199946Ability to activate gene expression at Retinoic acid receptor RXR-gamma was evaluated in a cotransfection assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID1370661Induction of apoptosis in human MCF7 cells assessed as ratio of cleaved caspase-9 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID199353Ability to activate gene expression at Retinoic acid receptor RXR-alpha was evaluated in a cotransfection assay.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
AID1355459Transactivation of RXR in human HepG2 cells assessed as induction of ABCA1 mRNA expression at 1 uM after 8 hrs by qRT-PCR analysis2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics.
AID1744025Agonist activity at RXR-alpha in mouse RAW264.7 cells assessed as inhibition of LPS-induced suppressed NO production at 0.1 uM incubated for 48 hrs by Griess assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
AID755619Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1738916Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID702950Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 40 uM after 12 hrs by luciferase reporter gene assay relative to control2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventi
AID755622Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1370669Anti-migratory activity against human MDA-MB-231 cells assessed as reduction in wound closure at 5 uM up to 24 hrs by wound-healing assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1062023Toxicity in Sprague-Dawley rat assessed as increase in body weight at 200 mg/kg, po after 7 days relative to control2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
AID198895Relative activity against Retinoic acid receptor gamma at 10e-6 M with respect to 10e-6 M of trans-RA1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1614974Agonist activity RXRgamma (unknown origin)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1512032Agonist activity at full-length human PPARgamma/RXR expressed in HEK293T cells at 0.3 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to untreated control2019ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.
AID1480583Partial antagonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells assessed as inhibition of WAY252623-induced receptor activation at 1 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID1614933Log D, lipophilicity of the compound by HPLC analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1665630Brain to serum concentration ratio, Kp of the compound in C57BL/6 mouse at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID1370659Induction of apoptosis in human BT549 cells assessed as ratio of cleaved caspase-9 to beta-actin level at 5 uM by western blot analysis (Rvb = 1 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
AID1614944Activity at LXR in human HepG2 cells assessed as effect on T0901317-induced activation of SREBP-1c mRNA expression at 1 uM after 12 hrs followed by renewal of medium containing test compounds after 6 hrs by PCR analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1537535Agonist activity at RXR in human HepG2 cells assessed as induction of APOE mRNA expression at 1 uM after 8 hrs by RT-PCR analysis2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
AID1480582Partial antagonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells assessed as inhibition of GW3965-induced receptor activation at 1 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
AID1152428Binding affinity to human RXR-alpha-ligand binding domain homodimers by fluorescence quenching method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
AID1775948Cmax in po dosed rat2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1615901Agonist activity at human RXRalpha LBD expressed in African green monkey COS1 cells incubated for 24 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
AID438594Agonist activity at human RARalpha expressed in human Caco-2 cells assessed as induction of RARE-mediated transcriptional activity at 1 uM after 24 hrs by luciferase reporter gene assay relative to all-trans retinoic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
AID1799444Ligand Binding Assay from Article 10.1016/s1074-5521(98)90083-7: \\Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.\\1998Chemistry & biology, Jan, Volume: 5, Issue:1
Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)2015PPAR research, , Volume: 2015Identification of Bexarotene as a PPARγ Antagonist with HDX.
AID1346768Human Retinoid X receptor-alpha (2B. Retinoid X receptors)1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1346775Human Retinoid X receptor-gamma (2B. Retinoid X receptors)2000Current pharmaceutical design, Jan, Volume: 6, Issue:1
Therapeutic applications for ligands of retinoid receptors.
AID1346775Human Retinoid X receptor-gamma (2B. Retinoid X receptors)1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1346743Human Retinoid X receptor-beta (2B. Retinoid X receptors)1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1346775Human Retinoid X receptor-gamma (2B. Retinoid X receptors)1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
AID1346768Human Retinoid X receptor-alpha (2B. Retinoid X receptors)1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID1346768Human Retinoid X receptor-alpha (2B. Retinoid X receptors)2000Current pharmaceutical design, Jan, Volume: 6, Issue:1
Therapeutic applications for ligands of retinoid receptors.
AID1346743Human Retinoid X receptor-beta (2B. Retinoid X receptors)2000Current pharmaceutical design, Jan, Volume: 6, Issue:1
Therapeutic applications for ligands of retinoid receptors.
AID1346743Human Retinoid X receptor-beta (2B. Retinoid X receptors)1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014The Journal of biological chemistry, Jan-10, Volume: 289, Issue:2
Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (618)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's35 (5.66)18.2507
2000's216 (34.95)29.6817
2010's270 (43.69)24.3611
2020's97 (15.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.50 (24.57)
Research Supply Index6.57 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index88.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials67 (10.44%)5.53%
Reviews69 (10.75%)6.00%
Case Studies106 (16.51%)4.05%
Observational3 (0.47%)0.25%
Other397 (61.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (42)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Study to Evaluate the Effect of Bexarotene - an RXR Agonist - on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects [NCT02061878]Phase 112 participants (Actual)Interventional2014-08-31Completed
Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00050960]Phase 3612 participants (Actual)Interventional2002-05-31Completed
A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas [NCT05296304]Phase 120 participants (Anticipated)Interventional2022-03-16Recruiting
A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma [NCT01134341]Phase 134 participants (Actual)Interventional2010-03-31Completed
A Phase I Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract [NCT01116622]Phase 124 participants (Actual)Interventional2003-04-30Completed
A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer [NCT00125359]Phase 242 participants (Actual)Interventional2005-08-31Completed
A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat; Zolinza) in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma [NCT00127101]Phase 123 participants (Actual)Interventional2005-09-30Terminated(stopped due to The study was stopped due to low enrollment.)
A Phase II Study of Gemcitabine and Bexarotene (Gembex) in the Treatment of Cutaneous T-cell Lymphoma [NCT00660231]Phase 236 participants (Actual)Interventional2008-03-31Completed
Preoperative Bexarotene Treatment for Cushing's Disease [NCT00845351]Phase 1/Phase 26 participants (Anticipated)Interventional2008-11-30Recruiting
Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression [NCT00718770]Early Phase 110 participants (Actual)Interventional2008-11-30Completed
Comparison Efficacy of Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients: Double-blind Placebo Controlled Study [NCT00534898]Phase 30 participants InterventionalWithdrawn(stopped due to The study withdrawn due to lack financial support)
A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT00411632]Phase 237 participants (Actual)Interventional2006-11-29Completed
Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial [NCT00141947]Phase 315 participants (Anticipated)Interventional2005-09-30Recruiting
A Multicenter Randomized Double-Blind Trial Of Targretin Capsules Modifying Immunophenotypic Markers Related To Breast Cancer Progression In Breast Tissue From Genetically Identified High Risk Patients [NCT00055991]Phase 187 participants (Actual)Interventional2001-09-30Completed
A Phase I Dose Escalation Study of Intravenous Decitabine in Combination With Oral Bexarotene in Patients With Acute Myeloid Leukemia (AML) [NCT01001143]Phase 119 participants (Actual)Interventional2010-05-31Completed
Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma [NCT01007448]Phase 459 participants (Actual)Interventional2010-01-06Completed
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial [NCT00535574]Phase 390 participants (Actual)Interventional2008-11-30Completed
Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma [NCT00030849]Phase 20 participants Interventional2001-10-31Completed
Investigator-Initiated, Double Blind, Vehicle-Controlled, Bilateral Comparison Trial of Bexarotene (Targretin) Gel 1% vs. Vehicle Gel in Combination With Narrow Band UVB Phototherapy for Moderate to Severe Psoriasis Vulgaris [NCT00151008]Phase 235 participants Interventional2003-11-30Completed
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype [NCT04664829]Phase 112 participants (Anticipated)Interventional2020-10-01Recruiting
Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer [NCT00514293]Phase 239 participants (Anticipated)Interventional2007-01-31Recruiting
A Phase I Study of Bexarotene in Patients With Acute Myeloid Leukemia [NCT00316030]Phase 154 participants Interventional2004-01-31Completed
A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma [NCT00030589]Phase 20 participants Interventional2001-02-28Active, not recruiting
A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides [NCT00056056]Phase 393 participants (Actual)Interventional2003-01-31Terminated(stopped due to poor accrual)
A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata [NCT00063076]Phase 2/Phase 346 participants (Actual)Interventional2003-05-31Completed
Randomized Phase III Trial Comparing Targretin Capsules/Cisplatin/Vinorelbine Versus Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00050973]Phase 3623 participants (Actual)InterventionalCompleted
A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer [NCT00003752]Phase 2180 participants (Anticipated)Interventional1998-10-31Completed
A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML [NCT00425477]Phase 226 participants (Actual)Interventional2006-11-30Completed
A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC) [NCT00238628]Phase 1/Phase 212 participants (Anticipated)Interventional2004-04-30Completed
Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma [NCT00306969]Phase 1/Phase 218 participants Interventional2001-12-31Completed
A Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis: a Topical Chemoprevention Strategy for Cutaneous T-cell Lymphoma. [NCT00322296]Phase 28 participants (Actual)Interventional2001-04-30Terminated(stopped due to The response rate (5/8) had reached a statistical significant endpoint.)
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene [NCT01504490]Phase 19 participants (Actual)Interventional2011-12-31Terminated(stopped due to Drug no longer available)
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. [NCT05106192]22 participants (Anticipated)Interventional2024-06-01Not yet recruiting
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma [NCT01578499]Phase 3131 participants (Actual)Interventional2012-06-11Completed
Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma [NCT00002212]Phase 227 participants InterventionalCompleted
Phase I and II Clinical Studies of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules for the Treatment of Patients With Advanced Non-Small Cell Lung Cancer [NCT00153842]Phase 1/Phase 233 participants (Actual)Interventional2001-08-31Terminated(stopped due to other trials show no survival benefit of bexarotene with platinum-based chemo)
A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer [NCT00125372]12 participants (Actual)Interventional2005-12-31Completed
Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®) [NCT00255801]Phase 237 participants (Actual)Interventional2005-11-30Completed
Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma [NCT00178841]Phase 24 participants (Actual)Interventional2005-06-30Completed
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer [NCT03323658]Phase 124 participants (Actual)Interventional2018-06-15Completed
A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease [NCT01782742]Phase 220 participants (Actual)Interventional2013-02-28Completed
A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia [NCT00615784]Phase 224 participants (Actual)Interventional2010-05-25Terminated(stopped due to Study terminated. Eisai's Targretin acquired by another pharmaceutical company.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00050960 (1) [back to overview]Overall Survival
NCT00125359 (3) [back to overview]Radiographic Response Rates
NCT00125359 (3) [back to overview]Progression-free Survival and Overall Survival
NCT00125359 (3) [back to overview]Correlation of Early PET Responses With Objective Radiographic Responses.
NCT00125372 (1) [back to overview]Number of Participants With EGFR Mutations and Correlation of EGFR Mutations With Response
NCT00127101 (2) [back to overview]Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities
NCT00127101 (2) [back to overview]Number of Participants Who Responded to Treatment
NCT00153842 (1) [back to overview]Bexarotene Oral Capsules Safety at Two Dose Levels (300 mg/m2 and 400 mg/m2) in Combination With Carboplatin and Taxol®.
NCT00178841 (3) [back to overview]Number of Participants With a 50% Improvement in Baseline Skin Score
NCT00178841 (3) [back to overview]Pruritus Score
NCT00178841 (3) [back to overview]Quality of Life Evaluations
NCT00255801 (1) [back to overview]Median Progression-free Survival
NCT00411632 (1) [back to overview]Number of Participants With 8-week Progression-Free Survival (i.e. Disease Control Rate) Stratified by Cancer Mutation Type
NCT00425477 (2) [back to overview]Clinical Activity as Measured by Change in Peripheral Blood Counts and Changes in Transfusion Requirements
NCT00425477 (2) [back to overview]Clinical Response (Complete and Partial)
NCT00615784 (2) [back to overview]Hematologic Response Rate of Bexarotene Monotherapy in Subjects With Relapsed/Refractory AML or Newly Diagnosed AML Who Are Unable to Receive Systemic Chemotherapy.
NCT00615784 (2) [back to overview]Bone Marrow Response Rate of Bexarotene in Subjects With AML Unable/Unwilling to Receive Systemic Chemotherapy
NCT00718770 (1) [back to overview]Change in Tumor Size
NCT01007448 (10) [back to overview]Duration of Tumor Response (CR, CCR, or PR) as Determined by Investigator's CA of Index Lesion Disease Severity
NCT01007448 (10) [back to overview]Duration of Tumor Response (CR, CCR, or PR) as Determined by Percent BSA Involvement
NCT01007448 (10) [back to overview]Duration of Tumor Response (CR, CCR, or PR) as Determined by PGA of Clinical Condition
NCT01007448 (10) [back to overview]Time to Tumor Progression as Determined by CA of Index Lesion Disease Severity
NCT01007448 (10) [back to overview]Time to Tumor Progression as Determined by Percent BSA Involvement
NCT01007448 (10) [back to overview]Time to Tumor Progression as Determined by PGA of Clinical Condition
NCT01007448 (10) [back to overview]Time to Tumor Response (CR, CCR, or PR) as Determined by CA of Index Lesion Disease Severity
NCT01007448 (10) [back to overview]Time to Tumor Response (CR, CCR, or PR) as Determined by Percent BSA Involvement
NCT01007448 (10) [back to overview]Time to Tumor Response (CR, CCR, or PR) as Determined by PGA of Clinical Condition
NCT01007448 (10) [back to overview]Number of Participants With Tumor Response (Complete Response [CR], Clinical Complete Response [CCR], and Partial Response [PR]) in up to 5 Index Lesions as Determined by Investigator's Composite Assessment (CA) of Index Lesion Disease Severity
NCT01578499 (15) [back to overview]Change From Baseline in the Skindex-29 Questionnaire Total Score
NCT01578499 (15) [back to overview]Cmax: Maximum Observed Concentration for Brentuximab Vedotin
NCT01578499 (15) [back to overview]Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin
NCT01578499 (15) [back to overview]Percentage of Participants Achieving a CR
NCT01578499 (15) [back to overview]Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin
NCT01578499 (15) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01578499 (15) [back to overview]Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin
NCT01578499 (15) [back to overview]DOR of Skin Response
NCT01578499 (15) [back to overview]Duration of Response (DOR)
NCT01578499 (15) [back to overview]Event-Free Survival (EFS)
NCT01578499 (15) [back to overview]Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin
NCT01578499 (15) [back to overview]Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire
NCT01578499 (15) [back to overview]Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)
NCT01578499 (15) [back to overview]Progression-Free Survival (PFS)
NCT01578499 (15) [back to overview]Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score
NCT01782742 (15) [back to overview]Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4
NCT01782742 (15) [back to overview]Change in MMSE Score in ALL Subjects From Baseline to Week 4
NCT01782742 (15) [back to overview]Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4
NCT01782742 (15) [back to overview]Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4
NCT01782742 (15) [back to overview]Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects
NCT01782742 (15) [back to overview]Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers
NCT01782742 (15) [back to overview]Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain
NCT01782742 (15) [back to overview]Primary Outcome by Genotype (ALL SUBJECTS)
NCT01782742 (15) [back to overview]Change in NPI Scores in ALL Subjects From Baseline to Week 4
NCT01782742 (15) [back to overview]Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)
NCT01782742 (15) [back to overview]Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)
NCT01782742 (15) [back to overview]Primary Outcome by Genotype (NON ApoE4 CARRIERS)
NCT01782742 (15) [back to overview]Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)
NCT01782742 (15) [back to overview]Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)
NCT01782742 (15) [back to overview]Primary Outcome by Genotype (ApoE4 CARRIERS)
NCT03323658 (4) [back to overview]Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities)
NCT03323658 (4) [back to overview]Number of Participants With Trace Level of Bexarotene Concentration in Plasma Detected
NCT03323658 (4) [back to overview]Number of Participants With Changes in Markers of Systemic Toxicity
NCT03323658 (4) [back to overview]Number of Participants With Bexarotene Concentration in Tissue

Overall Survival

(NCT00050960)
Timeframe: From date of randomization to date of death

InterventionMonths (Median)
Bexarotene With Carboplatin and Paclitaxel8.5
Carboplatin and Paclitaxel9.2

[back to top]

Radiographic Response Rates

Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00125359)
Timeframe: Through study completion, an average of 1 year

InterventionParticipants (Count of Participants)
Single Arm Erlotinib + Bexarotene19

[back to top]

Progression-free Survival and Overall Survival

(NCT00125359)
Timeframe: Through study completion, an average of 1 year

InterventionWeeks (Median)
Time to progressionOverall survival
Single Arm Erlotinib + Bexarotene722

[back to top]

Correlation of Early PET Responses With Objective Radiographic Responses.

PET response is assessed based on the guidelines of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group (Eur J Cancer 1999; 35(13):1773-82). PET response refers to the presence and measurement of the most current PET scan imaging when compared to baseline imaging. The amount of reduction in the disease from baseline to current imaging determines the extent to which the cancer has responded to treatment. Radiographic response is per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00125359)
Timeframe: Through study completion, an average of 1 year

InterventionParticipants (Count of Participants)
Computed tomography complete response72422520Computed tomography partial response72422520Computed tomography stable disease72422520Computed tomography disease progression72422520
Early PET progressionEarly PET metabolic responseEarly PET metabolic progressionEarly PET stable disease
Single Arm Erlotinib + Bexarotene0
Single Arm Erlotinib + Bexarotene1
Single Arm Erlotinib + Bexarotene5

[back to top]

Number of Participants With EGFR Mutations and Correlation of EGFR Mutations With Response

(NCT00125372)
Timeframe: Baseline and 9 days

InterventionParticipants (Count of Participants)
Wild-type EGFR72125196EGFR Mutation at Exon 2172125196EGFR not assessed at baseline72125196
Therapeutic ResponseNo Therepeutic Response
Erlotinib and Bexarotene4
Erlotinib and Bexarotene1
Erlotinib and Bexarotene0

[back to top]

Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities

Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1. (NCT00127101)
Timeframe: Day 1 to day 28

,,,,,
InterventionParticipants (Number)
DLTNo DLT
Cohort 103
Cohort 223
Cohort 2a03
Cohort 2b03
Cohort 605
Cohort 712

[back to top]

Number of Participants Who Responded to Treatment

"Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score.~SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400" (NCT00127101)
Timeframe: Every 28 days for up to 6 Months of Treatment

,,,,,
InterventionParticipants (Number)
ResponseNo Response
Cohort 103
Cohort 205
Cohort 2a03
Cohort 2b12
Cohort 623
Cohort 712

[back to top]

Bexarotene Oral Capsules Safety at Two Dose Levels (300 mg/m2 and 400 mg/m2) in Combination With Carboplatin and Taxol®.

At least 6 patients will be entered onto each dose level. Doses will not be escalated over the course of treatment of an individual patient. For the purpose of this protocol, an initial-dose-limiting toxicity (IDLT) is defined as a clinical observation that is, in the judgment of the Investigator, both attributable to the administration of bexarotene and necessitates a reduction in dose, suspension or discontinuation of study drug because of a NCI CTC Grade 3 or 4 level toxicity (with the exception of elevated lipids). (NCT00153842)
Timeframe: 36 months

Interventionparticipants experiencing IDLT (Number)
Phase IB: Bexarotene 300mg, Paclitaxel and Carboplatin1
Phase IB: Bexarotene 400mg, Paclitaxel and Carboplatin1
Phase II0

[back to top]

Number of Participants With a 50% Improvement in Baseline Skin Score

mSWAT scoring. Range 0 to 400. Measured every 4 weeks. (NCT00178841)
Timeframe: 16 weeks

Interventionparticipants (Number)
Rosiglitazone and Bexarotene0

[back to top]

Pruritus Score

10-cm visual analog scale, 10= worst, 1=best (NCT00178841)
Timeframe: 16 weeks

Interventionunits on a scale (Mean)
Rosiglitazone and Bexarotene5.7

[back to top]

Quality of Life Evaluations

FACT-G, Functional Assessment of Cancer Therapy-General (quality-of-life scale) 0= worst 108=best (NCT00178841)
Timeframe: baseline and every 4 weeks

Interventionunits on a scale (Mean)
Rosiglitazone and Bexarotene86.25

[back to top]

Median Progression-free Survival

"CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT~CT scans of chest, abdomen and pelvis for TNM stage IV patients who had positive findings prior to treatment.~CBC with Sézary cell count and/or flow cytometry in patients with Sézary syndrome.~Dermatologic responses will be determined by the Severity-Weighted Assessment Tool (SWAT), a standardized approach to measuring the extent and severity of overall skin disease in patients with CTCL Primary skin tumor assessments were made by the modified Severity-Weighted Assessment Tool (mSWAT) [12, 13]; the Composite Assessment of Index Lesion Severity (CA) [9, 14] was used a secondary scale. Progression was defined as ≥25% increase in mSWAT skin score and ≥50% increase in the sum of the products of the greatest diameters of involved lymph nodes over baseline for patients with involved lymph nodes with stage IV disease" (NCT00255801)
Timeframe: 3 years

Interventionmonths (Median)
Doxil and Targretin® (Bexarotene)5

[back to top]

Number of Participants With 8-week Progression-Free Survival (i.e. Disease Control Rate) Stratified by Cancer Mutation Type

The primary objective is to determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen. A radiologist independently assessed DC, which was defined as a complete or partial response or stable disease according to the RECIST(29) at the end of 8 weeks (start of treatment to end of second treatment cycle). PFS was assessed from the date of randomization to the earliest sign of disease progression or death from any cause. OS was assessed from the date of randomization until death from any cause. Tumor response was assessed every 8 weeks until disease progression. Toxicity was assessed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. (NCT00411632)
Timeframe: 8 weeks

Interventionparticipants (Number)
EGFRKRAS/BRAFVEGF/VEGFR-2RXR/Cyclin D1None
Erlotinib + Bexatrtene111015

[back to top]

Clinical Activity as Measured by Change in Peripheral Blood Counts and Changes in Transfusion Requirements

ANC count at baseline and after two cycles were measured and compared. Due to the limited number of clinical responders, the changes in transfusion requirements were not measured. (NCT00425477)
Timeframe: Baseline and after two cycles

Interventionneutrophils/mm^3 (Mean)
ANC at baselineANC after 2 cycles
Bexarotene + GM-CSF524931

[back to top]

Clinical Response (Complete and Partial)

Response to treatment was assessed after two cycles, according to International Working Group (IWG) criteria. (NCT00425477)
Timeframe: assessed after 2 cycles, up to 2 years

InterventionParticipants (Count of Participants)
PR (partial remission)HI (hematologic improvement)SD (stable disease)PD (progressive disease)
Bexarotene + GM-CSF0445

[back to top]

Hematologic Response Rate of Bexarotene Monotherapy in Subjects With Relapsed/Refractory AML or Newly Diagnosed AML Who Are Unable to Receive Systemic Chemotherapy.

Hematologic response will be assessed according to modified criteria of an international working group defined by Cheson et al, Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 1 December 2000, Vol. 96, No. 12, pp. 3671-3674 (NCT00615784)
Timeframe: Two months after 17th patient has started treatment with Bexarotene, for up to 1 year

InterventionParticipants (Count of Participants)
Bexarotene 300mg/m21

[back to top]

Bone Marrow Response Rate of Bexarotene in Subjects With AML Unable/Unwilling to Receive Systemic Chemotherapy

A clinically significant result will be recorded if the patient's bone marrow blasts percentage decreased by 50% or more over pretreatment blast percentage. (NCT00615784)
Timeframe: Two months after 17th patient has started treatment with Bexarotene, up to 1 year.

InterventionParticipants (Count of Participants)
Bexarotene 300mg/m21

[back to top]

Change in Tumor Size

To assess the tumor response of recurrent or metastatic radioiodine resistant thyroid cancer to bexarotene therapy using standard RECIST criteria (NCT00718770)
Timeframe: 1 year

Interventioncm (Mean)
Bexarotene4.7

[back to top]

Duration of Tumor Response (CR, CCR, or PR) as Determined by Investigator's CA of Index Lesion Disease Severity

Defined as time interval from onset of response to time participant relapses or last date of data collected with an assessment of participant still meeting response criteria. Index lesion symptoms/grade: erythema/scaling=0 (no evidence)-8 (very severe); plaque elevation=0 (no evidence)-8 (extreme elevation); hypopigmentation/hyperpigmentation=0 (no evidence)-8 (very severe change); area of involvement=0 (0 cm^2)-18 (>300 cm^2). CA: sum of signs/symptoms grades for index lesion. Index lesion CA grade at baseline divided into CA grade at study visit to determine treatment response. CA Ratio <1.0=improvement and >1.0=worsening of disease. Tumor response=percentage of participants with CR (CA ratio=0, no clinically abnormal lymph nodes, absence of CTCL histologic signs); CCR (CA ratio=0; no clinically abnormal lymph nodes); PR (CA ratio=≤0.5, <25% increase in number/aggregate area of abnormal lymph nodes/tumors, no new abnormal lymph nodes in documented area of absence of disease). (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day65.9
Bexarotene 300 mg/m^2/Day83.7

[back to top]

Duration of Tumor Response (CR, CCR, or PR) as Determined by Percent BSA Involvement

Defined as time interval from onset of response to time participant relapses or last date of data collected with an assessment of participant still meeting response criteria. To determine BSA, the area of the participant's palm was defined as 1% of the participant's BSA. The extent of involvement of disease was determined as multiples of the participant's palm area and expressed as a percentage of the participant's total BSA at Baseline (Day 1) and every 4 weeks thereafter during treatment. CR=percent BSA 0% and documented absence of histologic signs of CTCL. CCR=Percent BSA 0%. PR=a decrease from Baseline in percent BSA of at least 50%. (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day99.4
Bexarotene 300 mg/m^2/Day54.1

[back to top]

Duration of Tumor Response (CR, CCR, or PR) as Determined by PGA of Clinical Condition

Defined as time interval from onset of response to time participant relapses or last date of data collected with an assessment of participant still meeting response criteria. PGA was an assessment of the overall extent of improvement/worsening from Baseline of the participant's overall disease compared with the condition every 4 weeks thereafter during treatment. CR=PGA grade of 0 (completely clear of disease since Baseline) and absence of histologic signs of CTCL. CCR=PGA grade of 0. PR=PGA grade of 1 (almost clear [≥90%-<100%] of disease since Baseline), 2 (marked improvement [≥75%-<90%] of disease since Baseline), 3 (moderate improvement [≥50%-<70%] of disease since Baseline). (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day111.5
Bexarotene 300 mg/m^2/Day69.4

[back to top]

Time to Tumor Progression as Determined by CA of Index Lesion Disease Severity

Defined as time interval from first day of bexarotene treatment to time of first observation when participant met criteria for PD. Index lesion symptoms/grade: erythema/scaling=0 (no evidence)-8 (very severe); plaque elevation=0 (no evidence)-8 (extreme elevation); hypopigmentation/hyperpigmentation=0 (no evidence)-8 (very severe change); and area of involvement=0 (0 cm^2)-18 (>300 cm^2). CA: sum of signs/symptoms grades for index lesion. Index lesion CA grade at baseline divided into CA grade at study visit to determine treatment response. CA Ratio <1.0=improvement and >1.0=worsening of disease. Criteria for PD requires at least 1 component of the following: CA ratio=≥1.25, ≥25% increase in number/aggregate area of abnormal lymph nodes/tumors, or no new abnormal lymph nodes in documented area of absence of disease. (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day203.0
Bexarotene 300 mg/m^2/Day77.5

[back to top]

Time to Tumor Progression as Determined by Percent BSA Involvement

Defined as time interval from first day of bexarotene treatment to time of first observation when participant met criteria for PD. To determine BSA involvement, the area of the participant's palm was defined as 1% of the participant's BSA. The extent of involvement of disease was determined as multiples of the participant's palm area and expressed as a percentage of the participant's total BSA at Baseline (Day 1) and every 4 weeks thereafter during treatment. PD=an increase from Baseline in percent BSA of at least 25%. (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day86.0
Bexarotene 300 mg/m^2/Day88.0

[back to top]

Time to Tumor Progression as Determined by PGA of Clinical Condition

Defined as time interval from first day of bexarotene treatment to time of first observation when participant met criteria for PD. PGA was an assessment of the overall extent of improvement/worsening from Baseline of the participant's overall disease compared with the condition every 4 weeks thereafter during treatment. PD=PGA grade of 6 (worse disease [≥25%] than at baseline). If visceral disease or an abnormal lymph node was located in a documented area of absence of disease, then PD would be reported for the participant. (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 300 mg/m^2/Day115.5

[back to top]

Time to Tumor Response (CR, CCR, or PR) as Determined by CA of Index Lesion Disease Severity

Defined as time interval from first day of bexarotene treatment to time of first observation when participant met the criteria of CR, CCR, or PR. Index lesion symptoms/grade: erythema/scaling=0 (no evidence)-8 (very severe); plaque elevation=0 (no evidence)-8 (extreme elevation); hypopigmentation/hyperpigmentation=0 (no evidence)-8 (very severe change); and area of involvement=0 (0 cm^2)-18 (>300 cm^2). CA: sum of signs/symptoms grades for index lesion. Index lesion CA grade at baseline divided into CA grade at study visit to determine treatment response. CA Ratio <1.0=improvement and >1.0=worsening of disease. Tumor response=percentage of participants with CR (CA ratio=0, no clinically abnormal lymph nodes, and absence of CTCL histologic signs); CCR (CA ratio=0 and no clinically abnormal lymph nodes); and PR (CA ratio=≤0.5, <25% increase in number/aggregate area of abnormal lymph nodes/tumors, and no new abnormal lymph nodes in documented area of absence of disease). (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day99.9
Bexarotene 300 mg/m^2/Day91.6

[back to top]

Time to Tumor Response (CR, CCR, or PR) as Determined by Percent BSA Involvement

Defined as time interval from first day of bexarotene treatment to time of first observation when participant met the criteria of CR, CCR, or PR. To determine BSA, the area of the participant's palm was defined as 1% of the participant's BSA. The extent of involvement of disease was determined as multiples of the participant's palm area and expressed as a percentage of the participant's total BSA at Baseline (Day 1) and every 4 weeks thereafter during treatment. CR=percent BSA 0% and documented absence of histologic signs of CTCL. CCR=Percent BSA 0%. PR=a decrease from Baseline in percent BSA of at least 50%. (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day66.1
Bexarotene 300 mg/m^2/Day117.0

[back to top]

Time to Tumor Response (CR, CCR, or PR) as Determined by PGA of Clinical Condition

Defined as time interval from first day of bexarotene treatment to time of first observation when participant met the criteria of CR, CCR, or PR. PGA was an assessment of the overall extent of improvement/worsening from Baseline of the participant's overall disease compared with the condition every 4 weeks thereafter during treatment. CR=PGA grade of 0 (completely clear of disease since Baseline) and absence of histologic signs of CTCL. CCR=PGA grade of 0. PR=PGA grade of 1 (almost clear [≥90%-<100%] of disease since Baseline), 2 (marked improvement [≥75%-<90%] of disease since Baseline), 3 (moderate improvement [≥50%-<70%] of disease since Baseline). (NCT01007448)
Timeframe: Baseline up to Week 24

Interventiondays (Mean)
Bexarotene 150 mg/m^2/Day53.5
Bexarotene 300 mg/m^2/Day103.5

[back to top]

Number of Participants With Tumor Response (Complete Response [CR], Clinical Complete Response [CCR], and Partial Response [PR]) in up to 5 Index Lesions as Determined by Investigator's Composite Assessment (CA) of Index Lesion Disease Severity

Index lesion symptoms/grade include: erythema=0 (no evidence)-8 (very severe); scaling=0 (no evidence)-8 (very severe); plaque elevation=0 (no evidence)-8 (extreme elevation); hypopigmentation/hyperpigmentation=0 (no evidence of change)-8 (very severe change); area of involvement=0 (0 centimeters [cm]^2)-18 (>300 cm^2). CA generated by sum of grades of signs/symptoms for each index lesion. Index lesion CA grade at baseline was divided into CA grade at each subsequent study visit to determine participant's response to treatment. Ratio of CA <1.0=improvement in disease; ratio >1.0=worsening of disease. Tumor response as determined by CA=percentage of participants achieving CR (CA ratio=0, no clinically abnormal lymph nodes, and absence of histologic signs of CTCL); CCR (CA ratio=0 and no clinically abnormal lymph nodes); and PR (CA ratio=≤0.5, <25% increase in number/aggregate area of abnormal lymph nodes/tumors, and no new abnormal lymph nodes in documented area of absence of disease). (NCT01007448)
Timeframe: Baseline up to Week 24

,
InterventionParticipants (Count of Participants)
CRCCRPR
Bexarotene 150 mg/m^2/Day025
Bexarotene 300 mg/m^2/Day037

[back to top]

Change From Baseline in the Skindex-29 Questionnaire Total Score

Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement. (NCT01578499)
Timeframe: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)

,
Interventionscore on a scale (Mean)
Change at Cycle 2Change at Cycle 4Change at Cycle 6Change at Cycle 8Change at Cycle 10Change at Cycle 12Change at Cycle 14Change at Cycle 16Change at End of TreatmentChange at 3-6 months LTFUChange at 6-9 months LTFUChange at 9-12 months LTFUChange at 12-15 months LTFUChange at 15-18 months LTFUChange at 18-21 months LTFUChange at 21-24 months LTFUChange at 24-27 months LTFUChange at 27-30 months LTFUChange at >30 months LTFU
Brentuximab Vedotin-5.44-14.60-17.59-21.73-22.47-23.37-19.72-19.35-16.26-1.07-8.04-7.94-16.21-19.18-19.27-16.60-17.04-12.45-11.49
Methotrexate or Bexarotene-2.49-6.71-5.40-7.28-3.71-5.22-7.490.75-0.96-9.48-9.68-4.93-11.16-8.53-5.46-6.86-9.05-7.97-1.07

[back to top]

Cmax: Maximum Observed Concentration for Brentuximab Vedotin

(NCT01578499)
Timeframe: Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3

,
Interventionug/mL (Mean)
Cycle 1 Day 1Cycle 3 Day 1
MF: Brentuximab Vedotin 1.8 mg/kg38.4036.69
pcALCL: Brentuximab Vedotin38.3640.14

[back to top]

Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin

(NCT01578499)
Timeframe: Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3

,
Interventionng/mL (Mean)
Cycle 1 Day 1Cycle 3 Day 1
MF: Brentuximab Vedotin 1.8 mg/kg3.343.08
pcALCL: Brentuximab Vedotin2.532.96

[back to top]

Percentage of Participants Achieving a CR

Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011). (NCT01578499)
Timeframe: Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)

Interventionpercentage of participants (Number)
Brentuximab Vedotin17.2
Methotrexate or Bexarotene1.6

[back to top]

Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin

(NCT01578499)
Timeframe: Day 1 pre-dose of Cycles 2 and 4

,
Interventionng/mL (Mean)
Cycle 2 Day 1Cycle 4 Day 1
MF: Brentuximab Vedotin 1.8 mg/kg0.090.11
pcALCL: Brentuximab Vedotin0.110.14

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. (NCT01578499)
Timeframe: First dose of study drug through 30 days after last dose of study drug (Up to 450 days)

,
Interventionparticipants (Number)
AEsSAEs
Brentuximab Vedotin6318
Methotrexate or Bexarotene5618

[back to top]

Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin

Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity. (NCT01578499)
Timeframe: Baseline up to End of Treatment (Week 52)

,
Interventionparticipants (Number)
Immunogenicity-evaluable participantsBaseline Negative: ATA negativeBaseline Negative: ATA positiveBaseline Negative: Transiently PositiveBaseline Negative: Persistently PositiveBaseline Negative: Neutralizing ATA PositiveBaseline Positive: ATA NegativeBaseline Positive: ATA PositiveBaseline Positive: Transiently PositiveBaseline Positive: Persistently PositiveBaseline Positive: Neutralizing ATA Positive
MF: Brentuximab Vedotin 1.8 mg/kg4623199101413302
pcALCL: Brentuximab Vedotin148642400000

[back to top]

DOR of Skin Response

Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin. Per mSWAT, CR is defined as 100% clearance of skin lesions. PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF). (NCT01578499)
Timeframe: Until disease progression, death or data cutoff (Median follow-up 38.8 months)

Interventionmonths (Median)
Brentuximab Vedotin18.9
Methotrexate or Bexarotene18.3

[back to top]

Duration of Response (DOR)

Duration of response was assessed by the IRF in participants with confirmed response [CR or Partial Response (PR)] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011). (NCT01578499)
Timeframe: Until disease progression, death or data cutoff (Median follow-up 38.8 months)

Interventionmonths (Median)
Brentuximab Vedotin15.1
Methotrexate or Bexarotene18.4

[back to top]

Event-Free Survival (EFS)

EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011). (NCT01578499)
Timeframe: From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)

Interventionmonths (Median)
Brentuximab Vedotin9.4
Methotrexate or Bexarotene2.3

[back to top]

Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin

(NCT01578499)
Timeframe: Day 1 pre-dose of Cycles 2 and 4

,
Interventionug/mL (Mean)
Cycle 2 Day 1Cycle 4 Day 1
MF: Brentuximab Vedotin 1.8 mg/kg0.580.78
pcALCL: Brentuximab Vedotin3.570.99

[back to top]

Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire

Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement. (NCT01578499)
Timeframe: Baseline up to End of Treatment (Week 52)

Interventionscore on a scale (Mean)
Brentuximab Vedotin-28.08
Methotrexate or Bexarotene-8.62

[back to top]

Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)

ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011). (NCT01578499)
Timeframe: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)

Interventionpercentage of participants (Number)
Brentuximab Vedotin54.7
Methotrexate or Bexarotene12.5

[back to top]

Progression-Free Survival (PFS)

PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011). (NCT01578499)
Timeframe: Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)

Interventionmonths (Median)
Brentuximab Vedotin16.7
Methotrexate or Bexarotene3.5

[back to top]

Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score

FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement. (NCT01578499)
Timeframe: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)

,
Interventionscore on a scale (Mean)
Change at Cycle 2Change at Cycle 4Change at Cycle 6Change at Cycle 8Change at Cycle 10Change at Cycle 12Change at Cycle 14Change at Cycle 16Change at End of TreatmentChange at 3-6 months LTFUChange at 6-9 months LTFUChange at 9-12 months LTFUChange at 12-15 months LTFUChange at 15-18 months LTFUChange at 18-21 months LTFUChange at 21-24 months LTFUChange at 24-27 months LTFUChange at 27-30 months LTFUChange at >30 months LTFU
Brentuximab Vedotin1.431.754.235.966.617.949.045.080.3516.00-0.193.628.333.033.351.514.20-1.57-6.22
Methotrexate or Bexarotene-0.371.782.242.544.388.6110.757.88-2.29-2.92-2.59-5.32-1.342.94-0.190.611.421.93-2.85

[back to top]

Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4

The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening. (NCT01782742)
Timeframe: Baseline to Week 4

Interventionpoints (Mean)
Bexarotene0.375
Placebo-0.250

[back to top]

Change in MMSE Score in ALL Subjects From Baseline to Week 4

The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30. (NCT01782742)
Timeframe: Baseline to Week 4

Interventionpoints (Mean)
Bexarotene0.750
Placebo1.750

[back to top]

Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4

The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living (NCT01782742)
Timeframe: Baseline to Week 4

Interventionpoints (Mean)
Bexarotene-1.938
Placebo-6.500

[back to top]

Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4

The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. (NCT01782742)
Timeframe: Baseline to Week 4

Interventionunits on a scale (Mean)
Bexarotene0.000
Placebo0.000

[back to top]

Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects

This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in all subjects (NCT01782742)
Timeframe: Baseline to Week 4

Interventionratio (Mean)
Bexarotene0.001
Placebo-0.005

[back to top]

Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers

This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in non ApoE4 Carriers (NCT01782742)
Timeframe: Baseline to Week 4

Interventionratio (Mean)
Bexarotene0.005
Placebo-0.005

[back to top]

Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain

The primary study endpoint for all subjects is the change from baseline to Week 4 in amyloid burden as measured by standard uptake units regional (SUVr) on amyloid brain imaging obtained through 18F-AV-45 PET (NCT01782742)
Timeframe: Baseline to Week 4

InterventionSUVr (Mean)
Bexarotene-0.03
Placebo0.02

[back to top]

Primary Outcome by Genotype (ALL SUBJECTS)

This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers compared to E-4 non-carriers) (NCT01782742)
Timeframe: Baseline to Week 4

,
InterventionSUVr (Mean)
Frontal Medial OrbitalAnterior CingulateParietalPosterior CingulatePrecuneusTemporal
Bexarotene-0.043-0.040-0.003-0.017-0.027-0.038
Placebo-0.0210.0180.0440.0440.0400.016

[back to top]

Change in NPI Scores in ALL Subjects From Baseline to Week 4

The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance (NCT01782742)
Timeframe: Baseline to Week 4

Interventionpoints (Mean)
Bexarotene-2.625
Placebo-2.250

[back to top]

Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)

This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HETEROZYGOTE ApoE4 CARRIERS) (NCT01782742)
Timeframe: Baseline to Week 4

,
InterventionSUVr (Mean)
CompositeFrontal Medial OrbitalAnterior CingulateParietalPosterior CingulatePrecuneusTemporal
Bexarotene-0.015-0.061-0.0480.034-0.0070.005-0.010
Placebo-0.048-0.099-0.069-0.019-0.044-0.027-0.030

[back to top]

Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)

"This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HOMOZYGOTE ApoE4 CARRIERS)~There are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm." (NCT01782742)
Timeframe: Baseline to Week 4

InterventionSUVr (Mean)
CompositeFrontal Medial OrbitalAnterior CingulateParietalPosterior CingulatePrecuneusTemporal
Bexarotene0.005-0.0040.0050.0030.0370.006-0.020

[back to top]

Primary Outcome by Genotype (NON ApoE4 CARRIERS)

Measures changes from baseline on treatment compared to placebo at week 4 on composite and regional Beta Amyloid burden according to ApoE genotype (NON ApoE4 CARRIERS) (NCT01782742)
Timeframe: Baseline to Week 4

,
InterventionSUVr (Mean)
CompositeFrontal Medial OrbitalAnterior CingulateParietalPosterior CingulatePrecuneusTemporal
Bexarotene-0.097-0.076-0.096-0.068-0.113-0.127-0.104
Placebo0.0470.0050.0480.0650.0740.0620.031

[back to top]

Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)

Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes (NCT01782742)
Timeframe: Baseline to Week 4

,
Interventionpmol/L (Mean)
Beta Amyloid 40Beta Amyloid 42
Bexarotene7.1860.585
Placebo-5.330-0.900

[back to top]

Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)

Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes (non ApoE4 carriers) (NCT01782742)
Timeframe: Baseline to Week 4

,
Interventionpmol/L (Mean)
Beta Amyloid 40Beta Amyloid 42
Bexarotene-3.5030.293
Placebo-8.550-1.127

[back to top]

Primary Outcome by Genotype (ApoE4 CARRIERS)

This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers) (NCT01782742)
Timeframe: Baseline to Week 4

,
InterventionSUVr (Mean)
CompositeFrontal Medial OrbitalAnterior CingulateParietalPosterior CingulatePrecuneusTemporal
Bexarotene-0.005-0.033-0.0220.0180.0150.006-0.015
Placebo-0.048-0.099-0.069-0.019-0.044-0.027-0.030

[back to top]

Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities)

Dose Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug. In addition, a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days. (NCT03323658)
Timeframe: 4 weeks of treatment, Up to 30 days after completion of study drug for AE assessments

,,
InterventionParticipants (Count of Participants)
Maculopapular rash with pruritus at application siteErythema/redness at application site
Dose Level 100
Dose Level 211
Expansion Cohort10

[back to top]

Number of Participants With Trace Level of Bexarotene Concentration in Plasma Detected

Plasma concentrations of bexarotene were evaluated in all participants at baseline and at end of study. Plasma samples: ND = Not detected (below the quantitation limit of 0.5 ng/mL) TDL = Trace levels detected (below the LOQ of 0.5ng/mL; estimated value) (NCT03323658)
Timeframe: baseline and end of treatment, up to 4 weeks

,,
InterventionParticipants (Count of Participants)
Plasma Baseline VisitPlasma End of Treatment Visit
Dose Level 100
Dose Level 200
Expansion Cohort02

[back to top]

Number of Participants With Changes in Markers of Systemic Toxicity

Serum biomarkers to be tested will be total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, thyroid-stimulating hormone, T4, T3, and calcium. Will be summarized using mean, standard deviation and median (range) for continuous variables at each time point. Wilcoxon rank-sum test may be used to examine the difference of continuous variables between participants' characteristics groups. Will be plotted as functions of time (baseline, week 1, week 2, and week 4). Linear mixed effect model will be applied to model the biomarker change over time for all participants. Appropriate transformation and regression model will be used to ensure the model fit. (NCT03323658)
Timeframe: Baseline up to 28 days

InterventionParticipants (Count of Participants)
Dose Level 10
Dose Level 20
Expansion Cohort1

[back to top]

Number of Participants With Bexarotene Concentration in Tissue

Breast tissue concentrations were available only in those women who underwent breast biopsies. Tissue samples: Not detected (below the quantitation limit of 2.5 ng/g for a 10mg sample) and Trace levels detected (below the LOQ of 2.5ng/g; estimated value). (NCT03323658)
Timeframe: end of treatment, up to 4 weeks

,,
InterventionParticipants (Count of Participants)
Non DetectedTrace Levels DetectedQuantitation limit of 2.6-10 ng/gQuantitation limit of 11-20 ng/gQuantitation limit of 21-30 ng/gQuantitation limit of >30 ng/g
Dose Level 1111110
Dose Level 2000100
Expansion Cohort421101

[back to top]